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ABSTRACT
Characterizing Novel Pathways for Regulation and Function of Ataxin-2
Elise Spencer Melhado
Department of Microbiology and Molecular Biology, BYU
Master of Science
Ataxin-2 is an RNA-binding protein that is involved in many crucial cellular processes
such as R-loop regulation, mRNA stability, TOR signaling regulation, and stress granule
formation. Ataxin-2 is highly conserved, found in organisms ranging from Saccharomyces
cerevisiae to Caenorhabditis elegans and Homo sapiens. Recently, ataxin-2 has been linked to
the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). ALS is a fatal disease that
causes loss of motor neurons. In addition to ataxin-2 interacting with known ALS risk factor
proteins, research into the relationship between ataxin-2 and ALS shows that polyglutamine
expansions in ataxin-2 are gain-of-function mutations that lead to overactivity of ataxin-2 and
probable neurodegeneration. In fact, targeting ataxin-2 using gene silencing techniques
dramatically slows the progression of ALS in both mice and man.
The Grose laboratory has characterized a serine-threonine kinase, PAS kinase as
upstream kinase and putative activator of ataxin-2. We hypothesize that knockdown of PAS
kinase could, therefore, have similar effects to directly downregulating ataxin-2 and its cellular
functions. Characterization of Ataxin-2 has revealed that its gain or loss of function lead to
distinct cellular phenotypes. One study concluded that lowering ataxin-2 levels reduced the size
and number of stress granules in mammalian cells, which was observed through microscopy.
Another study found that activation and overexpression of ataxin-2 lead to reduced mTOR levels
because of its sequestration to stress granules. Lastly, preliminary data obtained by the Grose
laboratory suggests that yeast deficient in Pbp1 (the yeast homologue of ataxin-2) have altered
cell cycles.
This project describes the cellular readouts used to determine if PAS kinase
downregulation confers the same cellular phenotypes as ataxin-2 downregulation. First, we
found that PAS kinase does influence ataxin-2 abundance in mammalian cells. Using yeast as a
model, we found that Pbp1 influences the cell cycle through its binding partners, causing a
reduction in the percentage of cells in the G2 phase compared to the G1 phase. PAS kinase
conferred an opposite change, most likely due to the activity of other PAS kinase substrates.
Additionally, we found that Pbp1 deficiency is synthetically lethal when in conjunction with
deficiency of any one of its cell cycle-related binding partners. The cellular changes cause by
Pbp1 deficiency highlight not only the importance of ataxin-2 in the cell, but also the importance
of understanding the effects of downregulation of ataxin-2.
Keywords: PAS kinase, Ataxin-2, Pbp1, stress granules, TORC1, Amyotrophic Lateral Sclerosis,
cell cycle
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CHAPTER 1: ALS and Ataxin-2
My contributions:
Chapter 1 serves as an introduction to this project and to highlight the foundational
preliminary data I produced. The final data are presented in Chapters 2 and 3. This chapter is
entirely my own.
1.1 Introduction
1.1.1 Ataxin-2 is an important cellular regulator whose dysfunction causes disease
Ataxin-2 is highly conserved and multifaceted protein that performs many functions
within the cell (Figure 1-1) including RNA processing, mRNA stability, stress granule and
processing body localization, circadian rhythmicity, R-loop regulation, and physiological
functions, including apoptosis, embryonic development, actin development, insulin signaling,
metabolic processes, and cellular proliferation (3). Ataxin-2 acts within the nucleus to promote
transcript polyadenylation, which stabilizes mRNA (4); additionally, ataxin-2 directly binds to
uridine-rich parts of 3’ untranslated regions, which has been shown to stabilize mRNAs and
increase their protein productivity (5).
The roles of ataxin-2 go beyond interactions with protein-coding mRNAs when ataxin-2
binds to non-coding RNAs to prevent the formation of R-loops, which are potentially deleterious
because of the genome instability it causes (6). This interaction led to suggestions that ataxin-2
plays a role in normal progression of the cell cycle, and its disruption could lead to abnormal
genome replication and cell proliferation, but further investigation is needed (7, 8). Additionally,
ataxin-2 is involved in circadian rhythmicity through activation of pacemaker proteins in D.
melanogaster and through uncharacterized interactions in M. musculus and H. sapiens (9-11).
The diverse roles Ataxin-2 can be categorized as RNA controlling functions or physiological
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functions, although these categories often overlap. When ataxin-2 regulation goes awry, the cell
often suffers, and disease ensues. Ataxin-2 deregulation has been linked to numerous diseases
including ALS, diabetes, and obesity.

Figure 1-1: Ataxin-2 has diverse cellular functions.
Because of its diverse functions, disfunction of ataxin-2 often leads to disease. (14)

1.1.2 ALS is a fatal neurodegenerative disease with many unknown risk factors
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is characterized
by the loss of motor neurons in the motor cortex, spinal cord and brain stem; the loss of neurons
causes progressive paralysis that eventually leads to respiratory failure and death within five
years of onset. ALS usually presents between the ages of 55 and 75 but can affect people of any
age. It is estimated to effect more than 20,000 Americans (12). Currently, there is no cure for
ALS, and treatments are limited; one of the most effective treatments, riluzole, prolongs patient
survival by only two to three months (13).
ALS cases are divided into two groups: sporadic and familial. Only 5 to 10 percent of
ALS cases fall into the familial category: most cases are classified as sporadic (12). In 1993, the
2

first causative mutations were found in the superoxide dismutase (SOD1) gene, accounting for
approximately 10-20 percent of familial ALS cases (14).
Other mutations found to be causative in a significant number of cases include TAR
DNA-binding protein 43 (TARDBP), fused-in sarcoma/translated in liposarcoma (FUS/TLS),
and a hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (CRORF72) (3,
14, 15). The mechanisms by which mutated FUS and TDP-43 confer neurodegeneration are not
well-characterized, but both play important roles in mRNA transport, motor neuron
development, and axonal maintenance (16). ALS-linked mutations of FUS and TDP-43, which
are both normally expressed at higher levels in the nucleus and low levels in the cytoplasm, show
gain of cytoplasmic function (17). These mutated genes can cause many disease-related
phenotypes, but account for a relatively low number of cases themselves.
Thus far, researchers have uncovered about 15 genes as causative for familial ALS and
approximately the same number for sporadic ALS, but the mechanisms through which these
mutations contribute to neurodegeneration remain largely uncharacterized (3). Despite the
discoveries of these causative genetic mutations, identified genes account for fewer than 20% of
sporadic ALS cases and only about 50% of familial cases (18, 19)
1.1.3 Protein-protein interactions may cause differences in disease characteristics
Research into the genetics of ALS is significant, but incomplete. Genetics do not account
for variability in age of onset and severity of disease in patients with the same genetic mutation,
suggesting that other disease factors exist (3). Ataxin-2, an RNA-binding protein that interacts
with the previously discussed FUS and TDP-43 (TARDBP) proteins, has been identified as a risk
factor for ALS through interactions with cytosolic aggregates of mutated FUS and TDP-43 (20,
21). The toxicity enhancement of mutated FUS and TDP-43 by ataxin-2 seems to be RNA-
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dependent, but the exact mechanism remains uncharacterized (22). Ataxin-2 has been found not
only to enhance the cellular toxicity of FUS and TDP-43, but ataxin-2 polyglutamine repeat
sequence extensions are themselves a risk factor for ALS (3, 16).
1.1.4 Mutated ataxin-2 is a risk factor for ALS and other neurodegenerative diseases
Polyglutamine repeats are found in ataxin-2 in all cells, and gene with 15-27 repeats is
considered normal; however, mutations that cause expansions of this repeat section are linked to
ALS when the repeats are between 27 and 34, expansions between 35 and 49 glutamine are
linked to parkinsonism, and repeats greater than 33 are linked to Spinocerebellar ataxia type 2
(23). In addition to the length of the expansion being considered a risk factor for various
diseases, the purity of CAG repeats in the mRNA can contribute to disease type and age of onset
(23). CAA interruptions in the glutamine repeats lessen the toxicity of the mutation, are thought
to provide stability to the normally unstable CAG repeats, and may influence the levels of
mRNA or translated protein (23). ALS patients usually have 1-3 CAA interruptions in the CAG
repeat (23). Although the exact biochemical events that cause these mutations to be pathogenic
remain unknown, it is accepted that these repeats form aggregates that cause gain-of-function
toxicity. Recently, the polyglutamine expansions have been shown cause abnormal conformation
of protein (24). Additionally, the mRNA with CAG/CAA repeats is suggested to be toxic to cells
in a repeat length-dependent manner (25).
1.1.5 Ataxin-2 mediates stress granule formation
In response to stressful stimuli cells abort normal processes, like translation. This abrupt
end causes mRNA to be stranded in the cytoplasm where it forms into stress granules or
processing bodies (P-bodies) (26-28). P-bodies differ from stress granules, but often colocalize
with stress granules, implying a connection between the two. Under stressful conditions, ataxin-2
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promotes the formation of stress granules, as shown by its localization to stress granules,
association with known stress granule proteins and the reduction of stress granules in the absence
of ataxin-2 (26). Ataxin-2 also physically interacts with Dhh1, a key P-body component, and
colocalizes with its homologue DDX6 implying a direct or indirect connection between ataxin-2
and P-bodies (29, 30). One study modified ataxin-2 expression levels using siRNA; this study
found that manipulation of ataxin-2 expression reduced the number and size of stress granules
through interference with stress granule assembly but does not prevent the formation of stress
granules entirely (31). Ataxin-2 knockdown disrupts normal formation of stress granules and Pbodies, which may further contribute to the diseases caused by the ataxin-2 knockdown itself.
1.1.6 Ataxin-2 is a regulator of TORC1
Ataxin-2 is involved in numerous physiological functions through its mRNA stability and
translation influencing functions, however, this study will focus on only one of these regulatory
interactions: ataxin-2 as a regulator of TORC1.
TORC1 is a complex that regulates cellular growth in
response to nutrient availability and is sensitive to caffeine as
well as rapamycin, an immune-suppressant drug. Caffeine is
a purine analogue that leads to cell death through
uncharacterized mechanisms, but one proposed mechanism is
a mechanism in which caffeine directly targets Tor1 kinase (a
component of TORC1 complex) in addition to other
unknown targets that can interfere/phosphorylate critical
proteins. The inhibition of Tor1 kinase leads to the activation

Figure 1-2: Ataxin-2 sequesters TORC1
to stress granules in addition to
promoting stress granule formation.

of Pkc1p-Mpk1p pathway that controls the expression of cell cycle-related genes at the G1/S
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phase transition as well as cell wall biosynthesis and repair genes (32-34). Because Tor1 is
unique to the TORC1 complex and not found in TORC2, the caffeine inhibition of Tor1 only
affects the TORC1 complex (1). Consistent with TORC1 conferring sensitivity to caffeine,
previous studies found that S. cerevisiae cells that express overactive TORC1 are resistant to
rapamycin and caffeine.
Previous studies show that if the yeast homologue of ataxin-2 (Pbp1) is overexpressed in
conjunction with TORC1 overexpression, TORC1 sensitivity is restored to both inhibitors (35).
When overexpressed, Pbp1 can efficiently sequester overactive TORC1 to stress granules,
inhibiting its ability to confer caffeine resistance, which makes the cell once again sensitive to
caffeine. This indicates that ataxin-2 (Pbp1) is an important regulator of TORC1. As a regulator,
Pbp1 does not interfere with the assembly of TORC1, but interferes with its ability to activate
other proteins by sequestering TORC1 to stress granules; when sequestered, the complex cannot
function as a kinase and phosphorylate its substrates, rendering it non-functional. This can be
visualized by analyzing the general abundance of intact TORC1 through immunoblot or
visualization in fluorescence microscopy.
1.1.7 Ataxin-2 is a potential target for disease treatment
Therapeutic reduction of ataxin-2 abundance has been shown to be the most promising
treatment for ALS; not only does ataxin-2 enhance the toxicity of FUS and TDP-43—and,
conversely, reduction reverses the enhanced toxicity, but ataxin-2 also contributes to other
cellular disease manifestations, namely stress granules and P-bodies. Some suggested approaches
to therapeutically target ataxin-2 include the use of transcription activator-like effector nucleases,
CRISPR/CAS, and epigenetic silencing (3, 36).
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1.1.8 PAS kinase directly phosphorylates and activates ataxin-2
PAS kinase is a serine-threonine kinase that phosphorylates a threonine residue in ataxin2, causing its activation (37). When cells experience stress, an activation pathway is initiated that
leads to the eventual activation of ataxin-2. Stress activates a series of upstream regulators that,
in turn, activate an AMP-regulated kinase called Snf1. PAS kinase is then activated by
phosphorylation from Snf1 (38). Activated PAS kinase goes on to activate many proteins
through phosphorylation, including ataxin-2 (37). In short, a pathway exists in which Snf1
activates PAS kinase through phosphorylation, which, in turn, activates Pbp1 through
phosphorylation, allowing Pbp1 to perform its downstream functions (7). The activation pathway
is likely to be conserved throughout eukaryotic organisms. In fact, lowering PAS kinase levels in
yeast decreases Pbp1/Ataxin-2 function, including localization to stress granules as well as
sequestration of TORC1. Ataxin-2 has also recently been shown to sequester TORC1 to stress
granules in mammalian cells.

Figure 1-3: Ataxin-2 (Pbp1) is activated by stress in healthy cells.
Stress activates upstream regulators that activate Snf1. Activated Snf1
activates PAS kinase. Activated PAS Kinase activates Pbp1.
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1.1.9 Altering PAS kinase abundance could mimic altering ataxin-2 abundance in cellular
phenotypes
Both increasing and decreasing general abundance of ataxin-2 cause distinct cellular
phenotypes to arise in cells, such as reduction in size and number of stress granules, changes in
abundance of TORC1, and possible cell cycle disruption. Inactive ataxin-2 cannot perform these
functions, so preventing the activation of ataxin-2 would likely lead to similar losses. As an
activator of ataxin-2, PAS kinase is a putative therapeutic target. Inactivation of PAS kinase
could lower the cellular levels of active ataxin-2, leading to the same phenotypes as direct
downregulation of ataxin-2. Understanding these pathways that surround an important RNAbinding protein like ataxin-2 is vital in the quest to understand the underlying cellular phenotypes
that cause devastating disease, such as ALS. This study will investigate the relationship of PAS
kinase and ataxin-2 as well as the phenotypic outcomes associated with downregulation of
ataxin-2.
1.2 Preliminary data
This project characterized the effects of PAS kinase regulation of ataxin-2 (and Pbp1)
and the downstream effects. Specifically, this project focused on identifying the effect of PAS
kinase knockdown on ataxin-2 levels and describing the downstream effects of altered Pbp1
levels on the cell cycle.
1.2.1 Identify the effect of PAS kinase knockout or knockdown on general ataxin-2 levels
in a mammalian model
PAS kinase is known to phosphorylate many proteins involved in cellular metabolism,
including ataxin-2 (37). This phosphorylation activates ataxin-2, allowing it to perform its
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functions in the cell. If PAS kinase is removed or downregulated, it is logical to assume that the
general abundance of ataxin-2 may be altered.
To test the effect of PAS kinase downregulation on ataxin-2, PAS kinase-deficient
(PASK-/-) and wild type (WT) mice were utilized (Figure 1-4). To further mimic human habits,
the mice were fed two different diets: a normal chow diet, and a high-fat, high-sugar diet
reflective of Western diets. Because ALS affects motor neurons, the neural cells from the brain
were analyzed for ataxin-2 expression levels via immunoblotting (for materials and methods see
Section 2.3.5). Our preliminary results showed that mice on a normal chow diet did not have a
significant difference in the amount of ataxin-2 when comparing the two genotypes, but mice on
a high-fat, high-sugar diet did display a significant reduction of ataxin-2 levels in PAS kinasedeficient mice compared to wild-type mice. It is likely that the high-fat, high-sugar (HFHS) diet
causes stress on cells that activates the stress response pathway activation of ataxin-2; wild-type
mice that have functioning PAS kinase have nearly double the ataxin-2 when consuming HFHS

Figure 1-4: ALS model mice who consume a high-fat, high-sugar diet have lower levels of ataxin-2 than wild-type.
Four groups of mice consisting of two genetic groups (wild-type and PAS kinase-deficient) and two diet groups
(normal chow and high-fat, high-sugar). Tissue from the brain was homogenized and run on a polyacrylamide gel for
immunoblotting. Samples were normalized to a control sample.
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diet rather than a normal chow diet, but ataxin-2 levels in PAS kinase knockout mice remain
constant. These results demonstrate the manipulating PAS kinase can affect ataxin-2 protein
levels in conjunction with stress.
1.2.2 Characterize the effects of Pbp1 and PAS kinase on the cell cycle in yeast
A recent screen for Pbp1 interacting partners performed by Nidhi Choksi of the Grose
lab, revealed many binding partners associated with cell cycle (Table 1). Ataxin-2 has been
posited by many to control the cell cycle, and these binding partners may explain the molecular
mechanisms of this control. We have focused on BNR1, APC9, FUN19, and SPR28 (all Pbp1
interacting partners) that were analyzed for roles in cell cycle changes due to their non-essential
nature. Since Pbp1 has been shown to sequester proteins (such as TORC1) to stress granules,
our hypothesis is that Pbp1 sequesters cell cycle components to the stress granule, inhibiting
their function and altering cell cycle progression.
BNR1 is a nonessential protein that nucleates linear actin filaments involved in budding
and actin spindle orientation. Although its effects on cell cycle are not known, BNR1 mutations
result in altered spindle and actin cable formation as well as abnormally elongated buds, thus we
expect an altered cell cycle. In addition, we expect that Pbp1 or PAS kinase overexpression
should result a similar phenotype to BNR1 deletion in that BNR1 may be sequestered to stress
granules and thus inactivated. SPR28 is also in the family of bed-neck microfilament genes.
APC9 is a subunit of the Anaphase-Promoting Complex/Cyclosome (APC/C) that is required for
degradation of anaphase inhibitors including mitotic cyclins during the metaphase/anaphase
transition. Thus, active BNR1, SPR28 or APC9 (in the absence of activated Pbp1) may increase
metaphase/anaphase, perhaps explaining the truncated S phase or extended G2 of Pbp1 or PAS
kinase-deficient yeast as we have observed. FUN19 is included because it seems to interact with
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both Pbp1, and it is a cell cycle protein, likely involved in regulation of transcription, and it
could also be sequestered by Pbp1.
Table 1-1: Putative Pbp1 binding partners identified by the mass spectrometry
The gene name, human homolog, description, cellular localization (Local.) and the number of times the protein was
retrieved from two independent runs are provided. For localization: C, Cytoplasm; M, Mitochondrion; N, Nucleus; ER,
Endoplasmic Reticulum; PM, Plasma Membrane; W, Cell Wall; G, golgi; SG, Stress Granule; S, meiotic Spindle; ES,
Endosome; CD, Cell Division.

Gene

TRS31

Human
Homolog
RNA Processing
IMP4
N/A
Protein Transport
TRAPPC5

VPS29
SSY1

VPS29
N/A

SEC24
TIM9

SEC24
TIMM9
Cell Cycle
TMEM30
Cell division control protein 50
MCM5
MiniChromosome maintenance protein 5
N/A
Anaphase Promoting Complex subunit 9
FMNL1
BNI1-related protein 1
PHLPP2
Adenylate Cyclase & magnesium ion binding
SEPT7
component of 10 nm filaments of mother-bud neck
SEPT1
Septin-related protein sporulation induced
TADA2A
SWIRM domain-containing protein
Other
N/A
Inner membrane assembly complex subunit 22
N/A
Nucleotide excision repair
ERMP1
Aminopeptidase Y
CYBB
Ferric reductase PM
N/A
Nitrilase
N/A
low-affinity Zn(2+) transporter
N/A
Involved in cellular adjustment to osmotic stress
Protein of Unknown function
N/A
Protein of unknown function
N/A
Tail-anchored ER membrane protein of unknown function
XPR1
Signal Transduction

IMP
SSD1

CDC50
MCM5
APC9
BNR1
CYR1
CDC3
SPR28
FUN19
INA22
RAD33
APE3
FRE7
NIT1
ZRT2
MOT3
YHR131CP
FRT1
SYG1

Name description

Local.

#

snoRNA-binding rRNA-processing protein
mRNA-binding translational repressor

N
N/C

2
1

Core component of transport protein particle (TRAPP)
complexes I-III
Vacuolar Protein Sorting
Component of the SPS plasma membrane amino acid sensor
system
COPII vesicle coat component
Mitochondrial inner membrane translocase

C/G

1

ES/ V
PM

1
1

ER/G/C
M

1
1

ES
N
CD
CD
CD
CD
W/ S
C

1
1
1
1
1
1
1
1

M
N
V
PM
PM
N/C

2
1
1
1
1
1
1

C
ER
PM/ER/G

1
1
1
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Saccharomyces cerevisiae was used to study the effects of PAS kinase knockout and
Pbp1 knockout on the cell cycle (for materials and methods see Section 3.3.8). Preliminary data
shown in Figure 1-5 that suggests Pbp1, the yeast homologue of ataxin-2, and PAS kinase
knockout yeast have altered phases in the cell cycle. For this data, methods from Section 3.3.8
were followed, but Propidium Iodide was used as dye. Because Pbp1 is activated by PAS kinase,
the effects of the Pbp1 knockout are expected to be like the knockout of PAS kinase. Further
investigation is needed to better evaluate the effect of these knockouts on the cell cycle.
The other interacting partners identified above were analyzed by obtaining yeast strains
deficient in one of each of the identified genes and testing these yeast strains along with

WT

psk1psk2

pbp1

Figure 1-5: Pbp1 and PASK knockout yeast show differences in cell cycle stage lengths.
Flow cytometry was used to detect PI in stained yeast cells. Wildtype yeast (JGY 43), Pbp1 deficient (JGY 1122),
and PASK deficient (JGY 1244) are shown.

constructed double-knockout strains. Double-knockout strains were created by designing primers
for each flanking region of the knocked-out gene to amplify the flanking regions without the
gene but containing a selectable marker. These fragments were transformed into either Pbp1
deficient or PAS kinase deficient yeast so homologous recombination will substitute the genelacking portion with the gene-containing portion of the genome, as shown in Figure 1-6. These
double-knockouts were tested alongside all the single-knockout strains to check for other
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proteins causing cell cycle changes.
Growth assays will also be
performed to check for viability of
the constructed strains.
1.3 Conclusion

Figure 1-6: Target genes were removed from Pbp1 and PSK knockout yeast
through homologous recombination.

Knockdown of ataxin-2 activity has been shown to be a potential treatment for ALS. As
an upstream activator, PAS kinase may be manipulated to reduce ataxin-2 activity. This
hypothesis will be explored. Additionally, exploring the multifaceted roles of ataxin-2 plays is
crucial to understanding how ataxin-2 contributes to neurodegeneration in ALS and how it may
contribute to other disease. We will investigate binding partners of ataxin-2 to better understand
how it interacts with other cellular components, especially those components related to the cell
cycle.
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CHAPTER 2: Identification and Characterization of PAS kinase as a Regulator of Ataxin-2
Function

Nidhi R. Choski, Brittany A. Pielstick, Elise S. Melhado, Aaron D. Gitler, Laura C. Bridgewater,
Julianne H. Grose, Ph. D.
My contributions to this paper:
Working with Brittany Pielstick, I processed and analyzed the protein from PAS kinase
deficient mice (Figure 2-4). We also optimized the protocols for homogenization, running on
polyacrylamide, and immunoblotting samples. Because ataxin-2 is not a highly expressed protein
and is prone to degradation, the task of detecting ataxin-2 levels is difficult. We wrote sections
2.3.5 and 2.4.4, as well as the corresponding discussion section.
2.1 Abstract
Mutations in the ATXN2 gene in humans cause neurodegeneration. The ataxin-2 protein
contains a tract of repeated glutamine (Q) residues – a polyglutamine (polyQ) tract. Long polyQ
expansions in ataxin-2 cause spinocerebellar ataxia type 2 (SCA2), whereas intermediate-length
polyQ expansions increase risk for the motor neuron disease amyotrophic lateral sclerosis (ALS).
The mechanisms by which polyQ expansions cause neurodegeneration are not fully understood
but it is likely caused by a gain of one more toxic properties. Thus, strategies to reduce levels of
ataxin-2 could be an effective therapeutic approach. Indeed, in two recent preclinical studies,
targeting the ataxin-2 gene in mouse using antisense oligonucleotides was sufficient to alleviate
disease symptoms in models of ALS and SCA2. These results illuminate ataxin-2 as a potential
therapeutic target for at least two neurodegenerative diseases. We recently identified PAS kinase
1 (Psk1) as an activator of the yeast ataxin-2 homolog poly(A)-binding protein binding protein 1
(Pbp1). Here we characterized the regulation of Pbp1/ataxin-2 by Psk1 and provide evidence that
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PAS kinase 2 (Psk2) also phosphorylates and activates Pbp1. Importantly, we show that human
ataxin-2 complements Pbp1-deficiency in yeast and that it can also be activated by PAS kinase.
We provide evidence that human PAS kinase can phosphorylate ataxin-2 in vitro and knockout
of PAS kinase in mouse results in reduced ataxin-2 protein levels, consistent with the reduction
of Pbp1/Ataxin-2 activity observed in PAS kinase-deficient yeast. We propose PAS kinase as a
regulator of ataxin-2 and thus a novel therapeutic target for ALS and SCA2.
2.2 Introduction
Nutrient-sensing kinases maintain metabolic homeostasis by allocating cellular resources
in response to nutrient status through the phosphorylation and subsequent regulation of protein
substrates (39). PAS kinase is a nutrient-sensing kinase that contains a catalytic serine/threonine
kinase domain and a sensory/regulatory PAS domain (40) and is highly conserved from yeast to
man (41). PAS kinase is regulated by glucose levels and in turn regulates glucose homeostasis in
both yeast and mice (for reviews see (42-47)). Underscoring PAS kinase’s central role in
regulating metabolism, when placed on a high fat diet, PAS kinase-deficient mice (Pask-/-) show
an increased metabolic rate and are resistant to weight gain, liver triglyceride accumulation and
insulin resistance (48). In mammals, this regulation may occur in part through the
phosphorylation of PDX1 and glycogen synthase (44, 49). In yeast, PAS kinase has a conserved
role in the regulation of glucose metabolism through the phosphorylation of UDP-glucose
pyrophosphorylase (Ugp1), which controls the glucose flux between glycogen storage and cell
wall growth (50, 51). In addition, PAS kinase phosphorylates centromere binding factor (Cbf1)
to control yeast cellular respiration and lipid biosynthesis (52, 53).
We recently identified another substrate of PAS kinase and characterized its role as an
intermediate between SNF1 and TORC1, inhibiting cell growth and proliferation when energy is
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low. This pathway involves the SNF1-depedent phosphorylation and activation of PAS kinase
(37, 53), which then phosphorylates and activates Pbp1, a poly(A)-binding protein (Pab1)binding protein and a component of stress granules (SGs) (4, 54, 55). Once activated, Pbp1
induces SG formation, where target of rapamycin complex 1 (TORC1) is then sequestered (4, 35,
37, 54, 55). Specifically, deletion of PAS kinase in yeast leads to recovery of TORC1 and
reduced Pbp1 localization to stress granules (37).
The human homolog of Pbp1 is ataxin-2, encoded by the ATXN2 gene. Ataxin-2 is an
RNA-binding protein that regulates translation and other aspects of RNA metabolism (56-59).
Ataxin-2, like yeast Pbp1, is also involved in SG formation (31, 55). Human ataxin-2 harbors a
polyQ domain, which is almost always 22Qs long. PolyQ expansions greater than 34 cause
SCA2, which is associated with Purkinje neuron degeneration in the cerebellum. Intermediatelength polyQ expansions (60-66) increase risk for the fatal motor neuron disease ALS (2, 19, 22,
23, 60-94). For both SCA2 and ALS, disease is thought to be caused by a toxic gain of function
in ataxin-2. Reducing ataxin-2 levels either by genetic knockout or by administering antisense
oligonucleotides targeting the ataxin-2 gene to the central nervous system is sufficient to mitigate
degenerative phenotypes and improve survival in mouse models of SCA2 and ALS (36, 95).
Thus, strategies to reduce levels or activity of ataxin-2 could be an effective therapy for these
diseases.
In mouse, knockout of ataxin-2 is not lethal but intriguingly the knockout animals
develop obesity, insulin resistance, and dyslipidemia (96). This phenotype is in striking contrast
to the marked protection from these phenotypes on a high-fat diet conferred by the PAS kinase
knockout. We reasoned that if PAS kinase positively regulates ataxin-2, it could represent an
attractive therapeutic target for diseases in which reducing levels or activity of ataxin-2 would be
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efficacious (e.g., ALS and SCA2). Here we show that PAS kinase can phosphorylate and
regulate the activity of ataxin-2, similar to how it regulates the yeast homolog Pbp1. Importantly,
we demonstrate reduced ataxin-2 levels in the brains of PAS kinase knockout mice, highlighting
a new therapeutic avenue for targeting ataxin-2.
2.3 Materials and methods
2.3.1 Growth assays
Lists of strains, plasmids, and primers used in this study are provided in Supplementary
Table 1. For plasmid construction, standard PCR-based cloning methods were used. All
restriction enzymes were purchased from New England BioLabs (Ipswich, MA). For serial
dilution growth assays, spot-dilutions were performed by growing yeast in overnight liquid
culture, serially diluted 1:10 in water and spotted on selective plates as well as control plates.
Plates were incubated at 30°C for 7–10 days until colonies were apparent.
2.3.2 Histidine- and Myc-tagged protein purification
Yeast harboring plasmids for 6X histidine (HIS) or Myc-tagged protein expression were
grown in either SD-Ura media overnight, diluted 1:100-fold into 100 or 250 ml of SD-Ura, and
grown for 10–12 h, pelleted, and resuspended in 500 ml of SGal-Ura for 36 h to induce
expression under the GAL1-10 promoter. Yeast were pelleted and flash frozen at -80ºC. Yeast
were then resuspended in lysis buffer for HIS-tag purification (50 mM 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES), 300 mM NaCl, 20 mM imidazole, 10 mM KCl, 1
mM β-mercaptoethanol, and complete Protease Inhibitor Cocktail Tablet (Roche), pH 7.8, with
phosphatase inhibitors, 50 mMNaF, and glycerophosphate when necessary) or for Myc
purification (20 mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 10%
glycerol,1 mM β-mercaptoethanol, complete Protease Inhibitor Cocktail Tablet (Roche).
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Resuspended cultures were lysed using the Microfluidics M-110P homogenizer (Microfluidics,
Westwood, MA) for 500-ml cultures or bead blasted for 1 min, followed by 1 min on ice
repeated three times using 0.2-mm glass beads for small cultures (100 to 250 ml). Cell debris
were then pelleted at 12,000 rpm for 20–30 min. Supernatants were transferred to new tubes and
incubated with either 200 μl of nickel-nitrilotriacetic acid (Ni-NTA, Qiagen, Valencia, CA)
agarose beads for 500-ml HIS purification, or 5–10 μL of Myc-conjugated magnetic beads (Cell
Signaling, Danvers, MA) for Myc purification, for 2–3 h at 4°C. For HIS-epitope purification,
beads were washed twice with 15 ml of lysis buffer and then transferred to a polypropylene
column and washed with 30–50 ml of lysis buffer. For Myc-protein purification, beads were
separated using magnetic force and washed four times with 500 μl of lysis. HIS-tagged proteins
were eluted three times with 0.3 ml of Elution Buffer (lysis buffer containing 270 mM imidazole,
10 mM KCl and 50 mM NaCl pH 7.8). Beads containing Myc-tagged proteins were used directly
for in vitro kinase assays without eluting.
2.3.3 Pbp1 PAS kinase in vitro kinase assay
Myc-tagged Pbp1 and HIS-tagged Psk1 (pJG858), Psk2 (pJG173), and Psk2-KD
(pJG174) were purified from psk1psk2 yeast (JGY4). Purified ∆N419Pbp1-Myc–tagged proteins
were assayed for PAS kinase–dependent phosphorylation by incubating purified protein in 30 μl
of reaction buffer containing 1× PAS kinase buffer (0.4 M HEPES, 0.1 M KCl, 5 mM MgCl2,
pH 7.0), 0.2 mM ATP, 32P-ATP (5 μCi; MP Biomedicals, Santa Ana, CA)) in the presence or
absence of HIS purified full-length Psk2 or Psk1, or kinase-dead Psk2-K870R. Kinase assays
were started with the addition of PAS kinase and stopped with SDS–PAGE sample buffer.
Reactions were incubated for 12 min at 30°C, separated on SDS-PAGE gels, stained with
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Coomassie Blue and dried. The protein gels were then incubated on film overnight and
visualized the next day.
2.3.4 ATXN2 hPASK in vitro kinase assay
∆N544ATXN2 was purified from psk1psk2 yeast (JGY4) using HIS-tag purification. The
truncation was used due to an inability to express the full-length protein in yeast. Purified
ATXN2 protein was assayed for human PAS kinase–dependent phosphorylation by incubating
purified ∆N544ATXN2 protein in 30 μL of reaction buffer (0.4 M HEPES, 0.1 M KCl, 5 mM
MgCl2, pH 7.0), 1 mM ATP, 32P-ATP (5 μCi; MP Biomedicals, Santa Ana, CA) with or
without purified human PAS kinase. Samples were incubated for 30 min at 30°C. Kinase assays
were started with the addition of human PAS kinase and stopped with SDS–PAGE sample
buffer. Reactions were separated on 10% SDS polyacrylamide gels and proteins were stained
with Coomassie Blue and dried. The protein gels were then exposed for 6 hours and visualized
on film.
2.3.5 Protein extraction and Western blotting
PASK-/- mice were generously donated by Jared Rutter (University of Utah) and were
previously described (48). Male and female wild type and PASK-/- mice, generated by breeding
PASK+/- mice, were placed on a HFHS diet (D12266Bi Condensed Milk Diet from Research
Diets - 17% protein, 32% fat, 51% carbs) or standard diet (Teklad Rodent Diet 8604 from
Envigo) at 12 weeks old and maintained on the diet for 25 weeks. All procedures were approved
by the Brigham Young University Institutional Animal Care and Use Committee (protocol
number 13-1003 submitted by L.C.B.). Mouse brain was frozen down immediately after
dissection and stored at -80°C. The brain was thawed in triple detergent buffer (100Mm tris pH
7.4 HCl, 1% NP40, 0.5% SDS, 0.5% deoxycholic acid, 1mM EGTA, Halt Protease Inhibitor
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Cocktail (Thermo Fisher Scientific) and Phosphatase Inhibitor Cocktail 2 (Sigma Aldrich)) and
homogenized using the Bullet Blender from Next Advance and stainless-steel beads. The
samples were then spun at 20,817 rcf at 4°C for 10 minutes. The supernatant was extracted and
spun at 20,817 rcf at 4°C for an hour. Protein quantification was done using Bradford Assay kit
from Thermo Fisher Scientific. Samples were boiled for 3 min at 99°C and stored at -80°C. 50
ug of protein from each sample were run on SDS-page 8% gel at 50-100V for 1-2 hrs. The
samples were then transferred to a nitrocellulose membrane at 0.35 Amps for 1.5 hrs. The
membrane was washed with TBS (40 mM Tris, 100mM NaCl pH 7.5), blocked in 5% milk,
incubated at 4°C overnight with desired primary antibody dilution, and imaged with
WesternBright ECL (Advansta). Each sample had 2-4 technical replicates performed and was
normalized to a control sample on the blot. Antibodies used were: Anti-Ataxin-2 from BD
Transduction Laboratories and anti-GAPDH from Cell Signaling Technology.

Table 2-1: Phosphosite mutants of Pbp1

Plasmid
pJG1561
pJG1562
pJG1563

Mutation in amino acid
S106A, T193A, S436A, S479A, T708A, T718A
S106A, T193A, T355A, S436A, S479A, T708A
S106A, T215A, T355A, S436A, S479A, T708A, T718A

2.4 Results
2.4.1 Complementation of Pbp1 phenotype by ATXN2 in yeast
We previously found that PAS kinase-dependent phosphorylation of Pbp1 leads to the
sequestration of TORC1 into stress granules, inhibiting growth and proliferation (DeMille, 2015
#24). Ataxin-2 (ATXN2) is the human homologue of yeast Pbp1, and both ATXN2 and Pbp1
have conserved Lsm, LsmAD and self-interacting domains (Figure 2-1A) (26, 57). To test
whether ATXN2 could complement Pbp1 function in its ability to reduce cell growth and
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proliferation during caffeine-induced stress, we expressed three truncations of ATXN2
(∆N378ATXN2, ∆N543ATXN2 and ∆N699ATXN2) in pbp1 yeast and grew transformants on
selective media containing caffeine to assay for complementation of the TORC1 phenotype.
Expression of ∆N543ATXN2 and ∆N699ATXN2 rendered the cells sensitive to the TORC1
inhibitor caffeine but did not affect growth on standard media, suggesting that ATXN2 can
functionally replace yeast Pbp1 to inhibit TORC1 activity (Figure 1B). To our knowledge, this
is the first evidence that human ATXN2 can complement its yeast homolog Pbp1. In support of
this finding, overexpression of ATXN2, like Pbp1, has also previously been shown to rescue the
petite (pet-) phenotype of yeast lacking mitochondrial group II introns (26, 37).

Figure 2-1: Evidence for the conservation of Pbp1/ATXN2 function.
A) A schematic of ATXN2 functional domains as well as ATXN2 truncations used in
this study. Numbers indicate amino acids. Boxes are functional domains reported
(69) including Lsm, LsmAD and the self-interaction domain. B) Evidence of the
inhibition of TORC1 by human ∆N553ATXN2 in yeast. ATXN2, like Pbp1, causes
sensitivity to caffeine when overexpressed, most likely due to the inhibition of
TORC1 (17, 21). Pbp1 deficient yeast (JYG1122) were transformed with
∆N700ATXN2 (pJG1361), ∆N554ATXN2 (pJG1360), ∆N379ATXN2 (pJG1359),
pPbp1 (pJG925), or empty vector (pJG859) grown in SD-Ura, serially diluted 1:10,
and spotted on SGal-Ura + 1.87 mM caffeine plates, and on a control SD-Ura
plate. Plates were incubated at 30°C for 7–10 days until colonies were apparent.
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2.4.2 Evidence for direct phosphorylation of human ATXN2 by human PAS kinase
We previously provided evidence for the phosphorylation of Pbp1 by PAS kinase 1
(Psk1) in yeast (37). Psk1 and Psk2 are two partially redundant PAS kinase homologs that likely
arose via whole genome duplication in yeast (97). Both Psk1 and Psk2 act as nutrient sensing
kinases and share similar functions in the regulation of glucose homeostasis in the cell, including
the ability to phosphorylate the well-characterized substrate Ugp1 (41, 50, 51). However, gene
duplication often leads to differentiated function allowing selection for both copies to occur (98,
99). We therefore analyzed the impact of Psk2 on Pbp1. We recombinantly expressed and
purified His-HA tagged Psk1, Psk2 and kinase-dead Psk2 (K870R) (41) and used them for in

Figure 2-2: Investigation into the regulation and function of yeast Pbp1.
A) Evidence for in vitro phosphorylation of Pbp1 by Psk2. ∆N419Pbp1 was
expressed and purified from psk1psk2 yeast cells and then assayed for in vitro
phosphorylation by Psk2 in the presence of 32P ATP. Pbp1 was verified as Psk2
substrate using a kinase-dead mutant (Psk2- K870R) as a control. B) Evidence
for in vitro phosphorylation of ∆N553ATXN2 by hPASK. ∆N553ATXN2 was
expressed and purified from psk1psk2 yeast cells and then assayed for in vitro
phosphorylation by hPASK in the presence of 32P-ATP. Phosphorylation of
∆N553ATXN2 was verified by assessing hPASK auto-phosphorylation in the
absence of ATXN2, and in the presence of non hPASK substrate GAPDH. Kinase
reactions were visualized on 10% SDS–PAGE gels, stained with Coomassie
brilliant blue (CB), and exposed on x-ray film.
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vitro kinase assays with purified Pbp1 (53). Note that we used a truncation (∆N419Pbp1)
because the full-length protein was not functional in vitro (37). We observed Psk2-dependent
Pbp1 phosphorylation (Figure 2-2A), providing evidence for the direct phosphorylation of
∆N419Pbp1 by Psk2.
Given the ability of ATXN2 to complement Pbp1 function, we next asked if the
regulation by PAS kinase was also conserved. We assessed the ability of human PAS kinase to
directly phosphorylate human ATXN2. We HIS incubated purified ∆N553ATXN2 with human
PAS kinase (hPASK) in the presence of radioactive ATP and assayed the phosphorylation of
ATXN2 by autoradiography. We detected PAS kinase-dependent phosphorylation of ATXN2 in
the in vitro kinase assay (Figure 2-2B), providing evidence that hPASK can phosphorylate
human ATXN2 and that the phosphorylation site is somewhere between aa554-1312 of ATXN2.
2.4.3 Evidence for the regulation of Pbp1/ATXN2 by PAS kinase in yeast
To determine whether the phosphorylation of ATXN2 by PAS kinase can regulate the
inhibition of TORC1, we transformed wild type and psk1psk2 yeast with ∆N553ATXN2 or full
length Pbp1 and checked the effect of growth on media containing caffeine. Upregulation of
∆N553ATXN2 driven by the Gal promoter caused significant growth inhibition in wild-type
cells compared to psk1psk2 cells (Figure 2-3A). These results suggest that PAS kinase may
activate ATXN2 under stress conditions, which may then sequester TORC1 in stress granules
and reduce cell growth and proliferation like the effects of Pbp1. We assessed TORC1-dependent
caffeine sensitivity in psk1 (JGY2) and psk2 (JGY3) yeast cells. In the presence of PSK2 (in
PSK1-deficient yeast), upregulation of Pbp1 or ATXN2 in yeast cells induced caffeine
sensitivity (35) when compared with the psk1psk2 yeast (Figure 2-3B). These results are
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consistent with Psk2 acting in a similar manner as Psk1 to inhibit TORC1 activity by
phosphorylating either Pbp1 or ATXN2.
2.4.4 Evidence for regulation of mammalian ATXN2 by PAS kinase in mice
Having established that PAS kinase can phosphorylate ATXN2 in vitro and that ATXN2
can complement PAS kinase-dependent functions in yeast, we finally sought to assess the effects
of PAS kinase on ATXN2 in mammalian cells. We analyzed brain homogenates from wild type
and PAS kinase deficient (PASK-/-) male mice for ATXN2 levels by immunoblot. The PASK-/showed a marked decrease in ATXN2 protein compared to their wild type littermates when

Figure 2-3: Evidence for the regulation of ATXN2 by PAS kinase.
A) Evidence that PAS kinase-deficiency (psk1psk2) ameliorates caffeine toxicity due to
Pbp1 or ∆N553ATXN2 overexpression. B) Evidence that PSK1 and PSK2 can function to
activate Pbp1 or ∆N553ATXN2 and thus inhibit TORC1 as determined by the caffeine
sensitivity phenotype. Wild type (JGY1), psk1 yeast (JGY2), psk2 yeast (JGY3), or the
double mutant (JGY4) were transformed with an empty vector (EV, pJG859), a plasmid
overexpressing Pbp1 (pJG925) or a plasmid overexpressing ∆N553ATXN2 (pJG1360)
grown in SD-Ura, serially diluted 1:10, and spotted on SGal-Ura + 1.87 mM caffeine
plates, as well as on a control SD-Ura plate. Plates were incubated at 30°C for 7–10 days
until colonies were apparent.
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placed on a High-Fat High-Sugar (HFHS) diet, whereas we did not observe significant effects
when analyzing tissue from the mice on a normal chow diet (Figure 2-4). In addition, no
significant difference was seen when we immunoblotted for GAPDH levels. Thus, PAS kinase
can regulate ATXN2 levels in mouse brain.

Figure 2-4: PASK deficiency decreases Ataxin-2 abundance in brain tissue from mice on a HFHS diet.
Brain was homogenized from WT and PASK-/- male mice on a normal chow diet or placed on a high-fat
high sugar (HFHS) diet for 25 weeks. Proteins was normalized by Bradford assay using bovine serum
albumin as a standard, run on SDS-PAGE and transferred to nitrocellulose paper for imaging with antiataxin-2 antibody (BD transduction laboratories) and anti-GAPDH antibody (Cell Signaling Technologies).
All samples were run three times to check technical replicates, normalized to a loading control sample, and
quantified using ImageJ (73). Error bars represent SEM. Representative western blots are shown. Data
was analyzed using one-way analysis of variance (2) with Tukey’s HSD post hoc test. *p-value <= 0.05.
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2.5 Discussion
Herein we have provided evidence for regulation of Pbp1/ATXN2 by the nutrient
response serine-threonine protein kinase PAS kinase (see Figure 2-5 for a summary model).

Figure 2-5: A model for the regulation of Pbp1/ATXN2 by PAS kinase.
A) When PAS kinase is inhibited, Pbp1 is inhibited and TORC1 functions to increase cell growth and proliferation. B) When
PAS kinase is activated, it phosphorylates Pbp1/ATXN2 which then inhibits TORC1 function through sequestration at stress
granules.

We have previously demonstrated the direct phosphorylation of Pbp1 by Psk1 as well as
the reduced localization of Pbp1 at stress granule and recovery of TORC1 activity in PAS
kinase-deficient yeast (37). There are two homologs of PAS kinase in yeast, Psk1 and Psk2.
This is of interest because proteins that arise from gene duplication often evolve related but
differential function (99). For example, there are two TOR complexes in eukaryotic cells,
TORC1, which primarily regulates cell growth and proliferation in yeast and mammalian cells,
and TOR complex 2 (TORC2), which primarily regulates the actin cytoskeleton. Although a
single protein works in both complexes in most eukaryotic cells, yeast has two TOR proteins,
TOR1 and TOR2. TORC1 contains the protein encoded by TOR1 or TOR2 as well as
Kog1(Raptor), Tco89 and Lst8, and regulates protein synthesis and cell size in response to
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nutrients (100). In contrast, TORC2 contains only Tor2 along with Avo1, Avo2, Avo3, Bit61
and Lst8 and is responsible for polarization of the actin cytoskeleton as well as cell division
(101). We, therefore, hypothesized that Psk1 and Psk2 may have differential roles and explored
the role of Psk2 in Pbp1 regulation. In addition to its phosphorylation by Psk1, we provide
evidence for in vitro phosphorylation of Pbp1 by Psk2 (Figure 2A). In addition to in vitro kinase
assays, our phenotypic assays also suggest that Psk2 ameliorates caffeine toxicity due to Pbp1
upregulation similar to its homolog Psk1 (Figure 3).
Crosstalk between PAS kinase and TORC1 has been previously reported in mammalian
cells. However, the molecular mechanisms of this crosstalk are unknown. Our findings suggest it
could be through the phosphorylation and regulation of ATXN2, the mammalian homolog of
Pbp1. First, we provide evidence for the complementation of PBP1-deficient yeast by ATXN2
(Figure 1). Second, PAS kinase is able to phosphorylate ATXN2 in vitro (Figure 2A) and to
regulate its function in vivo (Figure 3B). Specifically, under caffeine induced stress,
upregulation of ATXN2 inhibits TORC1 and thus inhibits cell growth and proliferation. Caffeine
sensitivity can be rescued in psk1psk2 cells, suggesting that phosphorylation of ATXN2 by PAS
kinase activates it which then inhibits TORC1 (Figure 3B). Thus, this pathway, the suppression
of ATXN2 activity by PAS kinase, may be conserved in mammalian cells.
Our discovery of a kinase regulator of ATXN2 could have important therapeutic
implications for neurodegenerative diseases. Mutations in ATXN2 can cause SCA2 or ALS.
These mutations appear to confer a gain of function. Indeed, reducing ATXN2 levels can
mitigate phenotypes in mouse models of ALS and SCA2 (36, 95). Studies of Atxn2 knockout
mice have implicated ATXN2 in the development of obesity, insulin resistance, and
dyslipidemia. Our study provides evidence that ATXN2 protein levels are significantly decreased
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in brain tissue from PASK-/- mice that are on a western (HFHS) diet (Figure 4). However, no
significant difference was seen when mice are on the standard diet, suggesting diet may play a
role and/or that the effects of PAS kinase are smaller and require a larger sample number. The
available data on the effects of a western diet on ALS progression are relatively unknown, and
diet impacts in general appear to be complex (for recent reviews see (102, 103)). The published
studies suggest high calorie diets (high fat, high protein or high carbohydrate) may aid in weight
stabilization (104, 105), which is a common marker for poor prognosis in ALS patients (106,
107), but further studies are needed to understand the effect of diet on disease progression.
Although further study is needed, diet may be part of a combinatorial therapeutic approach for
improving outcomes in ALS.
The decrease in ATXN2 protein in PAS kinase-deficient mice on a HFHS diet is
consistent with the in vitro phosphorylation of ATXN2 by hPASK and the suppression of
ATXN2 function by PAS kinase deletion in yeast. Thus, the characterization of ATXN2 and its
potential regulation by PAS kinase may be key in understanding the development of this
devastating disease and nominate PAS kinase as a potential therapeutic target.
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Table 2-2: Putative Pbp1 binding partners identified by the yeast two-hybrid
The gene name, human homolog, description, cellular localization (Local.), number of times it was retrieved (#), yeast library
screened (cDNA or Genomic library), construct description (amino acids fused to the prey domain) and the growth strength
of each putative partner (Weak or Strong) is provided. Putative binding partners were placed into functional categories
based on their reported function. C corresponds to cytoplasm, MEM to membrane, M to mitochondrion, N to nucleus, ER to
endoplasmic reticulum, V to vacuole and SG to stress granule. S, strong; M, medium; W, weak

Human
homolog

Gene description

Local.

#

Pray
library

Construct
(aa)

Growth
strength

ERC2

mRNA methylation

N/C

3

cDNA

W

PAT1

SLC36A1

N/C

1

Gen

PKH1

Pdpk1

Deadenylationdependent mRNAdecapping factor
Cytoplasmic mRNA
processing body
assembly
Hypothetical Protein.
Putative RNA binding
protein

C/V

1

cDNA

C/SG

2

Gen

aa170 to
aa298
(aa366)
aa2 to
aa192
(aa796)
aa649 to
aa741
(aa766)
aa509 to
aa718
(aa718)
aa504 to
aa759
(aa759)
aa1 to
aa120
(aa442)
aa407 to
aa480
(aa480)

W

Gene
RNA Processing
MUM2

SGDID:S000003482

-

Other Functions
YEN1

GEN1

Response to DNA
damage stimulus

N/C

2

Gen

PTC6

PPM1K

M

1

Gen

SEC61

SEC61A2

mitochondrion
degradation,
macroautophagy
misfolded protein
transport

ER/MEM

1

Gen

S
M
W

S
M

Table 2-3: Putative Pbp1 binding partners identified by the mass spectrometry
The gene name, human homolog, description, cellular localization (Local.) and the number of times the protein
was retrieved from two independent runs are provided. For localization: C, Cytoplasm; M, Mitochondrion; N,
Nucleus; ER, Endoplasmic Reticulum; PM, Plasma Membrane; W, Cell Wall; G, golgi; SG, Stress Granule; S,
meiotic Spindle; ES, Endosome; CD, Cell Division.

Gene

Human
Homolog
RNA Processing
IMP
IMP4
SSD1
N/A
Protein Transporter
TRS31
TRAPPC5
VPS29
SSY1

VPS29
N/A

SEC24
TIM9
Cell Cycle

SEC24
TIMM9

Name description

Local.

#

snoRNA-binding rRNA-processing protein
mRNA-binding translational repressor

N
N/C

2
1

Core component of transport protein particle (TRAPP)
complexes I-III
Vacuolar Protein Sorting
Component of the SPS plasma membrane amino acid sensor
system
COPII vesicle coat component
Mitochondrial inner membrane translocase

C/G

1

ES/ V
PM

1
1

ER/G/C
M

1
1
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CDC50
TMEM30
MCM5
MCM5
APC9
N/A
BNR1
FMNL1
CYR1
PHLPP2
CDC3
SEPT7
SPR28
SEPT1
FUN19
TADA2A
Other
INA22
N/A
RAD33
N/A
APE3
ERMP1
FRE7
CYBB
NIT1
N/A
ZRT2
N/A
MOT3
N/A
Protein of Unknown function
YHR131CP N/A
FRT1
N/A
SYG1
XPR1

Cell division control protein 50
MiniChromosome maintenance protein 5
Anaphase Promoting Complex subunit 9
BNI1-related protein 1
Adenylate Cyclase & magnesium ion binding
component of 10 nm filaments of mother-bud neck
Septin-related protein expressed during sporulation
SWIRM domain-containing protein

ES
N
CD
CD
CD
CD
W/ S
C

1
1
1
1
1
1
1
1

Inner membrane assembly complex subunit 22
Nucleotide excision repair
Aminopeptidase Y
Ferric reductase PM
Nitrilase
low-affinity Zn(2+) transporter
Involved in cellular adjustment to osmotic stress

M
N
V
PM
PM
N/C

2
1
1
1
1
1
1

Protein of Unknow function
Tail-anchored ER membrane protein of unknown function
Signal Transduction

C
ER
PM/ER/G

1
1
1
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CHAPTER 3: A Pbp1 Interactome Reveals Novel Roles in Mitophagy and Cell Cycle
Regulation Through Protein Sequestration at Stress Granules
Pape JA, Melhado ES, Newey CR, Choksi N, Grose JH
My contributions to this paper:
I produced the data for Figures 3-2 and 3-3 and constructed the related strains. I
optimized the flow cytometry protocol for the strains, including unhealthy strains that exhibit
higher levels of RNA to interfere with DNA staining. This includes running some of the samples
on the flow cytometer and analyzing the data. I wrote all sections pertaining to this data (3.3.1,
3.3.7-3.3.9, 3.4.2, 3.4.3), and the corresponding discussion. Additionally, I merged and edited the
sections written by Jenny Pape that pertain to her data (Ptc6) with my own, and in doing so
added sections throughout to create a single narrative, rather than two separate projects.
3.1 Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal disease with few non-cure treatment
options. Investigations into the molecular mechanisms of ALS have revealed ataxin-2 to be
associated with ALS-related neurodegeneration through multiple pathways, including the
sequestration of mRNA and proteins at stress granules. Understanding the regulation and
function of ataxin-2 may therefore provide key insights into neurodegeneration. Herein, we
expand the known function of ataxin-2 through a protein-protein interactome study of the yeast
homolog, Pbp1, revealing 32 novel binding partners. Several proteins associated with the known
function of Pbp1 in mRNA processing were identified, as well as proteins not previously
associated with Pbp1, including proteins in cell cycle and mitophagy pathways. The novel
binding partner Ptc6 was investigated further due to its relationship to TORC1 and mitophagy.
Pbp1 was found to inhibit Ptc6 via sequestration to stress granules. Additionally, Pbp1 deficient
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strains displayed increased mitophagy while Pbp1/Ptc6 deficient strains displayed normal
mitophagy. Analysis of the cell cycle revealed Pbp1 affects the cell cycle through increased
G2/G1 ratio, and sequestration of APC9 at stress granules. The identification of Pbp1 binding
partners, especially those that affect general cell health and viability, contributes to the
understanding of ataxin-2/Pbp1 and how it is involved in disease.
3.2 Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. With no
known cure and only a handful of known genetic components, treatment options for patients
typically revolve around symptomatic management, such as physical therapy, pain relievers, and
dietary supplementation (108, 109). Therefore, there is a desperate need for an effective drug to
be developed that will ameliorate disease symptoms and extend patient lifespan. Recently,
intermediate-length ataxin-2 polyQ repeat expansions were identified to be significantly
associated with susceptibility of ALS in humans (110). While little is known about ataxin-2,
initial studies have revealed that therapeutic knockdown of ataxin-2 in TDP-43 transgenic ALS
model mice extends lifespan when compared controls (36). This suggests that higher levels of
ataxin-2 are associated with shorter lifespan, while lower levels of ataxin-2 are associated with a
longer lifespan. Using ataxin-2 as a therapeutic target is promising, though not without sideeffects, especially when considered complete inhibition of ataxin-2. Deletion of ataxin-2 in mice
has been shown to have adverse side-effects, including obesity, insulin resistance, and
hyperlipidemia (111, 112), suggesting that the deletion significantly impairs healthy cellular
metabolism. It is unclear what other pathways are being altered in response to ataxin-2
deficiency, suggesting that reducing ataxin-2 levels, rather than depleting them, may restore
healthy function of the gene instead of ameliorating its function.
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A newly identified regulator of ataxin-2 is PAS kinase. PAS kinase is a nutrient sensing
protein kinase that is conserved between yeast, mice, and humans (113). PAS kinase is a
promising regulator because PAS kinase deficiency protects against obesity, insulin resistance,
and hyperlipidemia in mice on a high-fat diet, many of the phenotypes associated with ataxin-2
deficiency in mice (114, 115). Furthermore, PAS kinase is influenced by both diet and sex, two
traits also seen to differ ALS pathology in both human and mouse studies (114). This suggests
that PAS kinase is working in conjunction with ataxin-2 to regulate many cellular functions,
especially those related to metabolic and mitochondrial health.
In yeast, PAS kinase has been shown
directly phosphorylate the homolog of
ataxin-2, Poly A binding protein binding
protein 1, Pbp1. Under cellular stress, PAS
kinase phosphorylates and activates Pbp1,
sequestering it to stress granules. This
function is not surprising, as Pbp1 is
reported to be involved with sequestration of

Figure 3-7: PAS kinase phosphorylates and activates
Pbp1/ataxin-2, causing sequestration of Pbp1/ataxin-2.
Pbp1/ataxin-2 also influences the sequestration of other
proteins to the stress granules.

mRNA and proteins to stress granules (55,
116). This model has been verified by monitoring the known interactions of Pbp1 and TORC1
(Figure 1). Pbp1 overexpression has been shown to cause caffeine sensitivity and resulting
inhibition of cellular growth through the sequestration of TORC1 to stress granules (116). In
PAS kinase deficient yeast, Pbp1 is no longer phosphorylated and activated by PAS kinase, thus
preventing the sequestration of TORC1 to stress granules by Pbp1 and promoting cellular growth
on caffeine (117).
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Understanding the PAS kinase-ataxin-2 pathway is key to understanding the molecular
pathways involved in stress granule formation as well as neurodegenerative disease. While some
functions of ataxin-2 have been outlined, little is known about how it interacts with other
proteins to alter conditions in the cell. Currently, only four binding partners of Pbp1 have been
characterized—Pab1, Lsm12, Pbp4, and Dhh1, all proteins involved in stress granule formation
(55). Herein we report a yeast Pbp1 interactome obtained from both yeast two-hybrid as well as
copurification techniques. In addition, two key binding partners, Ptc6 and Apc9, are further
characterized and the effects of Pbp1 on mitophagy and cell cycle are analyzed. Identifying
additional binding partners and understanding their effects on normal cellular functions will shed
light onto how Pbp1 is affecting neurodegeneration and help identify disease-associate genes.
3.3 Materials and methods
3.3.1 Growth assays
Lists of strains, plasmids, and primers used in this study are provided in Table 1-3,
respectively. For plasmid construction, standard PCR-based cloning methods were used.
Restriction enzymes were purchased from New England BioLabs (Ipswich, MA). Yeast
knockouts were from the Saccharomyces Genome Collection (118). Double knockouts were
obtained using primers designed 300 bp upstream and downstream of the respective gene and
transforming the PCR products PCR products into JGY1122 harboring a Pbp1 overexpression
plasmid (pJG925) to recover lost function that was suspected to be preventing the successful
creation of double knockouts. Strain knockouts were verified by PCR and plated on 5’FOA agar
to remove the plasmid. To transform plasmids or PCR products into strains, 200 microliters of an
overnight culture of yeast were centrifuged at 10,000 rpm for 2 minutes prior to resuspension in
the transformation mixture, consisting of DTT, PEG, and Tris. PCR amplifications of regions of
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interest or plasmids were added into the transformation mixture and this was incubated at 45° C
for 45 minutes. After an appropriate recovery time in YPAD, the mixture was plated on the
appropriate selection media and allowed to grow for 48-72 hours. Yeast two-hybrid bait plasmid
was made by PCR amplification of Pbp1 and subsequent cloning into the EcoRI/SalI sites of
pGBD-C1 yeast two-hybrid Gal4 bait vector (pJG424) (119) (pJG1386 (JG2916/3163)). Yeast
two-hybrid libraries are described in an earlier work (120). Yeast two-hybrid Gold cells
(Clontech, Mountain View, CA) were used to transform in bait and prey plasmids for interaction
studies.
For single mutant phenotype serial dilution growth assays, spot-dilutions were performed
by growing yeast in overnight liquid culture for 48 hours, serially diluting 1:10 in water and
spotting on selective plates as well as control plates. For synthetic lethal spot-dilutions the first
dilution was 1:10 and all subsequent were 1:5. Plates were incubated at 30°C for 1–10 days until
colonies were apparent.
Table 3-1: Yeast strains used in this study

Strain

Bkgd

Genotype

Abbreviation

a/ α

JGY1

W303

ade2-1 can1-100 his3-11,15 leu2-3112 trp1-1
ura3-1

WT

a

JGY2

W303

PSK2psk1

a

JGY3

W303

PSK1psk2

a

JGY4

W303

psk1psk2

a

JGY299

S288C

Psk1::his3 ade2-1 can1-100 his3-11,15 leu23112 trp1-1 ura3-1
psk2::kan-MX4 ade2-1 can1-100 his3-11,15
leu2-3112 trp1-1 ura3-1
psk1::his3 psk2::kan-MX4 ade21, can1-100
his3-11,15 leu2-3112, trp1-1 ura3-1
PSK2-TAPtag::kanMX ura3-0 trp1-0 SUC2 mal
mel gal2 CUP1 flo1 flo8-1

WT

α

LYS2::GAL1UAS-GAL1TATA-His3, GAL2UASGal2TATA-Ade2 URA3::MEL1UAS-MEL1TATA,
AUR1-CMEL1, ura3-52 his3-200 ade2-101
trp1-901 leu2-3, 112 gal4del gal80del metURA3::GAL1-GAL1-LacZ, MEL1, ura3-52, his3200, ade2-101, trp1-901, leu2-3, 112, gal4del,
gal80del, met-

Y2H Gold

a

Reference
or source
David
Stillman
(University
of Utah,)
Grose et al.
(2007)
Grose et al.
(2007)
Grose et al.
(2007)
Jared Rutter
(University
of Utah,)
Clontech

Y187

α

Clontech

Y2H Gold
(JGY1031)
Y187
(JGY1073)
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JGY1074
JGY1098
JGY1122

BY4743

JGY1161

S288C

JGY1383
JGY43
JGY1244

BY4741
BY4741

JGY1598

BY4741

JGY1599

BY4741

JGY1600

BY4741

JGY1601

BY4741

JGY1602

BY4741

JGY1659

BY4741

JGY1660

BY4741

JGY1661

BY4741

JGY1662

BY4741

JGY1603

BY4741

JGY1591
JGY1593
JGY1624
JGY1594

BY4741
BY4741
BY4741
BY4741

JGY1608

BY4741

JGY1623

BY4741

JGY1625

BY4741

pGADT7 Mate and Plate stationary phase
YPAD library in JGY1073
pGADT7 Mate and Plate mid-log YPAGal
library in JGY1073
Pbp1::KanMx4 His3-1, leu2-0, lys2-0,ura3-0

YPAD library

α

YPAGal library

α

pbp1

α

psk1::hygro psk2::NAT ura3-0 trp1-0 SUC2
mal mel gal2 CUP1 flo1 flo8-1
pJG1386 Pbp1 in Y2H bait ura3-52, his3-200,
ade2-101, trp1-901,leu2-3,112, gal4del
His3d1, leu2DO, met15DO, ura3DO
Psk2::NAT, psk1::hygro, his3D1, leu2DO,
met15DO, ura3DO.
Ptc6::kanMX, his3D1, leu2Do, met15DO,
ura3DO
Spr28::kanMX, His3d1, leu2DO, met15DO,
ura3DO
Apc9::kanMX, His3d1, leu2DO, met15DO,
ura3DO
Fun19::kanMX, His3d1, leu2DO, met15DO,
ura3DO
Bnr1::kanMX, His3d1, leu2DO, met15DO,
ura3DO
Spr28::kanMX Pbp1::his3, His3d1, leu2DO,
met15DO, ura3DO
Apc9::kanMX Pbp1::his3, His3d1, leu2DO,
met15DO, ura3DO
Fun19::kanMX Pbp1::his3, His3d1, leu2DO,
met15DO, ura3DO
Bnr1::kanMX Pbp1::his3, His3d1, leu2DO,
met15DO, ura3DO
PTC6-GFP::HIS3MX6, his3-1, leu2-0, met15-0,
ura3-0

psk1psk2

α

PBP1-Y2H
Gold
WT
psk1psk2

a

OM45-GFP::His, leu2DO, met15DO, ura3DO
OM45-GFP::His, leu2DO, met15DO, ura3DO
OM45-GFP::His, leu2DO, met15DO, ura3DO
OM45-GFP::His, psk1::hygro, psk2::nat,
leu2DO, met15DO, ura3DO
OM45-GFP::His, psk1::hygro, psk2::nat,
pbp1::kanMX, leu2DO, met15DO, ura3DO
OM45-GFP::His, psk1::hygro, psk2::nat,
ptc6::kanMX, leu2DO, met15DO, ura3DO
OM45-GFP::His, atg32::kanmx, leu2DO,
met15DO, ura3DO

WT
pbp1
ptc6
psk1psk2
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DeMille et
al. (2014)
DeMille et
al. (2014)
Janet Shaw
(University
of Utah, Salt
Lake City,
UT)
DeMille et
al. (2015)
This study
Jared Rutter

ptc6
spr28
apc9
fun19
bnr1
spr28pbp1
apc9pbp1
fun19pbp1
bnr1pbp1
ptc6-GFP

psk1psk2pbp1
psk1psk2ptc6
atg32

O’shea
collection
(ThermoFisher)

Table 3-2: Plasmids used in this study

Plasmid

Gene

Description

Backbone

pJG9
pJG173
pJG174

PSK1
PSK2
PSK2

Psk1 in pRS424
Psk2 in pJR1765B
Psk2 K870R kinase dead mutant

pRS424
pJR1765B
pJR1765B

Yeast
origin
2u
2u
2u

pJG421

EV

pGAD-C1 empty Y2H prey vector

YEp-GAD

2u

Leu

pJG424

EV

pGBD-C1 empty Y2H bait vector

YEp-GBD

2u

Trp

pJG428

Library

pGAD-C2 genomic library

YEp-GAD

2u

LEU

pJG429

Library

pGAD-C3 genomic library

YEp-GAD

2u

LEU

pJG598

PSK1

ΔN692Psk1 in pJG425

YEp-GBD

2u

Trp

pJG725

EV

pADH-Myc

pRS416

CEN

Ura

pJG734

PBP1

ADH ∆N420Pbp1-Myc

pRS416

CEN

Ura

pJG858

PSK1

pGAL1-10, Psk1-HIS/HA

pRS426

2u

Ura

pJG859

EV

pGAL1-10, HIS/HA

pRS426

2u

Ura

pJG925

PBP1

Full-length Pbp1 in pJG859

pRS426

2u

Ura

pJG960

PSK1

pGAL1-10, ∆N693Psk1-HIS/HA

pRS426

2u

Ura

pJG1250

PBP1

pGAL1-10, ∆N419Pbp1-Myc

pRS426

2u

Ura

pJG1251

PBP1

pGAL1-10, Full length Pbp1-Myc

pRS426

2u

Ura

pJG1271

PSK1

Psk1-D1230A kinase dead mutant

pRS426

2u

Ura

pJG1331

ATXN2

Full length ATXN2

pGEM-T

2u

Ura

pJG1359
pJG1360
pJG1361
pJG1386
pJG1409

ATXN2
ATXN2
ATXN2
PBP1
PBP1

pRS426
pRS426
pRS426
pRS416
pRS416

2u
2u
2u
CEN
CEN

Ura
Ura
Ura
Ura
Ura

pJG1542

PBP1

pRS416

CEN

Ura

This Study

pJG1523

PBP1

pRS416

CEN

Ura

This Study

pJG1544

PBP1

∆N379 ATXN2 in pJG859
∆N554 ATXN2 in pJG859
∆N700 ATXN2 in pJG859
∆N419Pbp1 in pJG424
Full length Pbp1 in pJG725
Pbp1 with mutations: S106A,
T193A, S436A, S479A, T708A,
T718A made with pJG1251
Pbp1 with mutations: S106A,
T193A, T355A, S436A, S479A,
T708A made with pJG1251
Pbp1 with mutations: S106A,
T215A, T355A, S436A, S479A,
T708A, T718A made with
pJG1251

Reference
or source
Jared Rutter
Jared Rutter
Jared Rutter
James et al.
(1996)
James et al.
(1996)
James et al.
(1996)
James et al.
(1996)
DeMille et
al. (2014)
David
Stillman
David
Stillman
DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2015)
DeMille et
al. (2015)
DeMille et
al. (2015)
DeMille et
al. (2015)
DeMille et
al. (2014)
Sino
Biological
Inc.
This Study
This Study
This Study
This Study
This Study

pRS416

CEN

Ura

This Study
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Selection
Trp
Ura
Ura

pRS426

2u

Ura

DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)
This Study

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study

pJG1546

PAT1

PTA1 in Y2H bait

Leu

pJG1548

Hypothetical
gene

Hypothetical gene in Y2H bait

Leu

pJG1549

YEN1

YEN1 in Y2H bait

Leu

pJG1560

PBP1

pJG1561

PBP1

pJG1562

PBP1

pJG1563

PBP1

Full length Pbp1 in pJG859
Pbp1 with mutations: S106A,
T193A, S436A, S479A, T708A,
T718A made with pJG12560
Pbp1 with mutations: S106A,
T193A, T355A, S436A, S479A,
T708A made with pJG1560
Pbp1 with mutations: S106A,
T215A, T355A, S436A, S479A,
T708A, T718A made with
pJG1560

pJG1572

SEC61

SEC61 in Y2H bait

Leu

pJG1573

PTC6

PTC6 in Y2H bait

Leu

pJG1574

MUM2

Mum2 in Y2H bait

Leu

pJG1575

PKH1

PKH1 in Y2H bait

Leu

pJG1669

PBP1

PBP1-RFP

pJG1690

SEC63

Sec63-RFP

pRS426

Ura
Ura

Table 3-3: Primers used in this study

Primer
JG2335
JG2761
JG2762
JG2916
JG2917
JG2953
JG2954
JG2993
JG3037
JG3136
JG3384
JG3704
JG3758
JG3759
JG3760
JG3761
JG3854
JG4531
JG4536

2u

Sequence
TTCGATGATGAAGATACC
CTATTCGATGATGAAGATACCCCACC
AGATGGTGCACGATGCACAG
GCCTCGAGGTTTATGGCCACTGGTACTACTATTATGG
GGCGAATTCATGAAGGGAAACTTTAGGAAAAGAG
GAAGGAAGGAAAGCTCAATTGGGAG
GATTGAAATACTGATTACTTAAAATTTGC
CGCCAGGGTTTTCCCAGTC
CAACCATAGGATGATAATGCGATTAG
GGCGAATTCTCGTTGCCTCCAAAACCGATCAGC
GGCGAATTCATGTCGTTGCCTCCAAAACCGATCAGC
GGCGTCGACTTACAACTGCTGTTGGTGGTGGGC
GGCCAATTGATGCGCTCAGCGGCCGC
GGCCAATTGATGACCCCCAGTGGGCCAGTTCTTG
GGCCAATTGATGTCGCCTTGCCCATCTCCTTCC
GGCCAATTGATGCTCACAGCCAATGAGGAACTTGAG
GGCGTCGACGCAACTGCTGTTGGTGGTGGGC
GATCGATTCAAAGTTACGACAGTCA
ACCCTATTTATATCTCTTCTTTCTAG
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DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)
This Study
Katrina
Cooper

JG4537
JG4538
JG4539
JG4540
JG4542
JG4543

CAACTGCCGTTCCCACTGC
TGAAAGTTCCATAATTGAAATACGTCG
CTTTGAGAAACAAGACGTAAAATACG
TCGATATAAGGACGAATAATGTCC
TTAAAGAGCGCCGCTACCATTTG
AGCCCTGATGTTGAAGATTTTCTC

3.3.2 Yeast 2-Hybrid screening
A yeast 2-hybrid system was used to look for a protein-protein interaction. The yeast 2hybrid modifies the transcription factor for the Gal4 promoter. The transcription factor has a
DNA binding domain and an activation domain that recruits RNA polymerase. The yeast 2hybrid system cleaves the activation and binding domain and fuses them with a protein that will
either serve as the bait (bound to binding domain) or prey (bound to activation domain). When
the two proteins interact in the cell it now allows for the Gal4 transcription factor binding
domain and activation domain to become close enough to each other to recruit RNA polymerase
to the promoter region and allow for expression of the reporter genes (121). Pbp1 was cloned
into binding domain (pJG1386) and the library was previously cloned into activation domain
(120) (pJG428, pJG429, JGY1079 and JGY1098). Yeast containing both plasmids were
selectively grown on SD-Leu-Trp. Colonies were then streaked onto selective media SD-LeuTrp-His-Ade, where growth indicates a protein-protein interaction due to expression of reporter
genes.
3.3.3 Yeast 2-Hybrid screening by mating
For cDNA library screens, α haploid yeast harboring a cDNA Y2H prey library
(JGY1074 and JGY1098) (120) was mated to a haploid yeast harboring ΔN419Pbp1 Bait
(JGY1383) in 2X YPAD for 24 hours at @ 30°C. Yeast cells where then pelleted and diluted
using 10mL of SD-Leu-Trp media followed by plating 100uL on 100 SD-Leu-Trp-His-Ade
plates.
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3.3.4 Yeast 2-Hybrid screening by transformation
For genomic library screens, the Y2HGold (Clontech) strain bearing ΔN419Pbp1 Bait
(JGY1383) was transformed with genomic libraries (pJG428, or pJG429) obtained from David
Stillman, University of Utah (119). Yeast cells where then pelleted and diluted using 10mL of
SD-Leu-Trp media followed by plating 100uL on 100 SD-Leu-Trp-His-Ade plates.
3.3.5 Colony check and dependency assay
Colonies that arose on Y2H selection plates (SD-leu-trp-his-ade) were again patched on
SD-leu-trp-his-ade plates for validation. The library plasmid inserts were then identified by
colony PCR with subsequent sequencing (Brigham Young University DNA sequencing center)
and national center for biotechnology information (NCBI) BLAST (122) analysis (an
unambiguous hit with e-value of ≥10e−45). For verification and elimination of false positives,
library plasmids were purified from yeast (123), amplified in Escherichia coli (Genelute plasmid
mini-prep kit, Sigma-Aldrich, St. Louis, MO), and transformed into Clontech matchmaker gold
yeast with either the Pbp1 bait plasmid (pJG1386) or the empty bait plasmid (pJG424). Colonies
arising on the SD-leu-trp transformation plates were then streaked onto SD-leu-trp-his-ade in
duplicate and allowed to grow for 3–5 d to test for Pbp1 dependence. The strength of growth was
determined by comparing growth of yeast on SD-leu-trp-his-ade plates, which is an indication of
the interaction strength (s, strong; m, medium; w, weak).
3.3.6 Mass spectrometry
Full length Pbp1 (pJG1560) into HIS expression under the GAL1-10 promoter was made
by PCR amplifying Pbp1 with primers JG2916/2917 and cloning into the EcoRI/XhoI sites of
pJG859. The protein was purified, run on 10% SDS PAGE, stained with Coomassie blue and 78
kDa protein purified with it was cut from protein gel using a sterile razorblade. The gel slice was
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flash frozen at -80°C and sent to the University of San Diego Biomolecular and Proteomics Mass
Spectrometry Facility for analysis.
3.3.7 Cell cycle analysis sample fixing
Strains were grown in plasmid-selective SD-Ura media for 24 hours, then the cultures
were centrifuged for 5 minutes at 500 rpm and the supernatant discarded. The cells were
resuspended in inducive S-Gal-Ura media and allowed to grow for 24 additional hours. Cultures
were then fixed in 95% EtOH at a ratio of 3 mL EtOH to 1 mL culture and placed in -20° C for
overnight to one week.
3.3.8 DNA staining
Depending on the OD as read from a spectrophotometer, 50-200 ul of the culture were
prepared according to the Rosebrock protocol (124). Samples were centrifuged for 20 minutes at
15,000 rpm and the supernatant discard. Then, samples were washed with Sodium Citrate Buffer
twice and allowed to rehydrate. After complete rehydration, samples were treated with RNase
and SYTOX-green and incubated in the dark. Initially, samples were treated with RNase for an
one-hour digestion time. Later repetitions were digested for up to four hours because of clouding
RNA presence. Proteinase K was subsequently added to halt RNase and cells were cooled to 4°
C. Prior to running, the samples were sonicated for 30 seconds at 3V using a needle tip sonicator.
3.3.9 Flow cytometry
Samples were run on a Cytoflex cytometer. Samples were run at 400-800 events/second
and 80,000 events were collected for each sample. Data gating was kept minimal, only to remove
dead cells from the dataset and to reduce dye noise by plotting FITC-H against FITC-A, as
shown in the Rosebrock protocol (124). The stages were discerned using Flow Jo’s Cell Cycle
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automatic mathematic model Watson Pragmatic algorithm. At minimum, three replications for
each constructed strain were collected and used in calculations.
3.3.10 PTC6 and APC9 localization studies
Apc9-GFP (JGY 1656) and Ptc6-GFP fusion yeast (JGY1603) were obtained from the
O’Shea collection (ThermoFisher). For colocalization with Pbp1 at stress granules, Pbp1-RFP
was transformed into JGY1656 or JGY1603 to monitor colocalization of Pbp1, Apc9 and Ptc6 to
stress granules. Overnight samples were grown according to Demille et al. Briefly, samples
were grown in in SD-Ura medium overnight, pelleted and re-suspended in SGal-Ura to induce
expression of Pab1-RFP. Cultures were then grown 4 days, pelleted, washed, and re-suspended
in synthetic complete medium. Cultures were grown for an additional hour at 30°C. Confocal
fluorescent imaging stacks were acquired using an Olympus FV1000 confocal microscope. A
60x lens was used with 10x zoom, 0.4 µm step size and resolution of 640x640 pixels/frame for
image acquisition. Deconvolution of images was performed using cellSens (Olympus).
3.3.11 Mitophagy assay
Mitophagy assays were performed via the method outlined by Kanki et al. Briefly,
Om54-GFP DNA fragment was amplified from JGY1586 using JG4522 and JG4523. PCR
product was transformed into JGY43, JGY1122, JGY 1598, and JGY1244 using standard yeast
transformation methods. Correct integration was verified through fluorescence microscopy and
PCR analysis of the genomic DNA (JG4524/JG4525).
Single colonies were picked and used to inncoluate 5mL YPD and grown to mid-log
phase. Aliquots equal to OD~0.1 were collected for t=0, and the remaining cultures were
centrifuged and re-suspended in a flask containing YPL (OD ~0.2). Cultures were grown
shaking for 48 hours at 30°C, then aliquots equal to OD~0.1 were collected by centrifugation, re-
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suspended in 50 µL of 10% TCA, incubated on ice for 10 minutes, and frozen until ready to be
broken open for SDS-Page. To break open, samples were thawed on ice and pelleted by
centrifugation at 21,000xg for 10 minutes. Supernatant was removed, pellets were washed twice
with 500 uL of cold acetone, and air dried. Samples were then re-suspended in 50 µL sample
buffer (150 mM Tris-HCl, pH 8.8, 6% SDS, 25% glycerol, 6 mM EDTA, 0.5% 2mercaptoethanol, and 0.05% bromophenol blue), disrupted by vortex with an equal amount of
glass beads for 3 minutes, and incubated at 100°C for 3 minutes.
5 µL of sample was loaded on a 12% polyacrylamide gel and resolved. Transfer was
completed using the TurboBlot program, 2 midi-gel mixed MW program, transferring onto a
nitrocellulose membrane. Membranes were blocked with 5% milk, then probed with anti-GFP
antibody (1:5000 TBST) at 4°C overnight, washed, then probed with HRP-conjugated antimouse (1:10,000 TBS) for 1 hour at room temperature. Membranes were developed using the
WesternBright ECL HRP substrate (Advansta Inc., San Jose, CA, USA, catalog number K12045-D50) according to the manufacturer’s protocol. Membranes were then striped and probed
with anti-UGP1 to ensure equal loading between samples. Bands were quantified using the
ImageJ software version 1.50i (National Institute of Health, Bethesda, MD, USA).
3.4 Results
3.4.1 Uncovering a Pbp1 interactome from yeast two-hybrid and copurification
Human ataxin-2 plays a pivotal role in the development of human ataxias, yet little is
known about its function (36, 110, 125). To elucidate the function of ataxin-2, a large-scale
interactome screen was performed using the yeast two-hybrid (Y2H) approach and
copurification. Y2H screens were conducted with ΔN419Pbp1 as bait and two previously
published yeast genomic libraries (pJG428, and pJG429) (119) as well as two cDNA libraries
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(JGY1098 and JGY1074) as prey (120). The ΔN419Pbp1 was utilized as bait because only false
positive hits were retrieved from several screens from the full-length Pbp1 construct was
nonfunctional in our hands in that. From ~10 million transformants or mated yeast screened,
seven Pbp1 binding partners were identified (Table 4). Four partners are RNA binding proteins
or involved in mRNA processing which is consistent with the known role of Pbp1, while the
other three have roles in stress response, mitophagy and misfolded protein transport. The
strength of growth is an indication of the interaction strength. Advantages of the Y2H approach
include the identification of direct protein–protein interactions and sensitivity due to
transcriptional amplification of an interaction (120). However, the yeast two-hybrid can also
yield false positives that allow growth independent of the bait. To minimize false positives, the
Y2HGold strain was used, which harbors four different reporters control (Clontech Matchmaker
Gold Yeast Two-hybrid System), and each of these binding partners was verified by purifying
the prey plasmid from yeast and retransforming into naive Y2HGold along with the ΔN419Pbp1
bait or an empty bait plasmid (119).
An alternative sensitive and reliable approach for identifying protein binding partners is
copurification followed by quantitative mass spectrometry (MS). Full-length Pbp1 fused with
histidine (HIS), epitope was affinity purified in triplicate, and samples were subjected to
quantitative liquid chromatography (LC)–tandem MS. Twenty-five putative binding partners
were identified for Pbp1 (Table 5). The Y2H screen retrieved all novel binding partners, whereas
the copurification screens retrieved both expected and novel binding partners. The copurification
screen retrieved two proteins involved in RNA processing five associated with protein transport
and eight involved in cell cycle.
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Table 3-4: Pbp1 binding partners identified by the yeast two-hybrid
C corresponds to cytoplasm, MEM to membrane, M to mitochondrion, N to nucleus, ER to endoplasmic reticulum, V to vacuole
and SG to stress granule. S, strong; M, medium; W, weak
Construct
Pray
Number
Human
Gene name
(Total
Growth
Localization
library
Gene
of hits
Homolog
description
number
strength
used
of aa)

RNA Processing

MUM2

PAT1

PKH1

Hypothetical
Protein
(SGDID:S0000034
82)

YEN1

PTC6

SEC61

ERC2

mRNA
methylation

Deadenylationdependent
SLC36A1
mRNAdecapping
factor
Cytoplasmic
mRNA
Pdpk1
processing body
assembly
Putative RNA
binding
protein,localizes
to stress
granules
induced by
glucose
deprivation
Other Functions
Response to
GEN1
DNA damage
stimulus
mitochondrion
degradation,
PPM1K
macroautophag
y
misfolded
SEC61A2
protein
transport
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N/C

3

cDNA

aa170 to
aa298
(aa366)

W

N/C

1

Gen

aa2 to
aa192
(aa796)

S

C/V

1

cDNA

aa649 to
aa741
(aa766)

M

C/SG

2

Gen

aa509 to
aa718
(aa718)

W

N/C

2

Gen

aa504 to
aa759
(aa759)

W

M

1

Gen

aa1 to
aa120
(aa442)

S

ER/MEM

1

Gen

aa407 to
aa480
(aa480)

M

Table 3-5: Pbp1 binding partners identified by the mass spectrometry
For localization: C, cytoplasm; M, mitochondrion; N, nucleus; ER, endoplasmic reticulum; PM, plasma membrane; W, cell wall; G,
golgi; SG, stress granule; S, meiotic spindle; ES, Endosome; CD, cell division sites.

Gene

Human
Homolog

RNA Processing
IMP
IMP4
SSD1
N/A
Protein Transporter
TRS31

TRAPPC5

VPS29

VPS29

SSY1

N/A

SEC24
TIM9
Cell Cycle
CDC50
MCM5
APC9
BNR1
CYR1

SEC24
TIMM9

CDC3

TMEM30
MCM5
N/A
FMNL1
PHLPP2
SEPT7

SPR28

SEPT1

FUN19
Other
INA22
RAD33
APE3
FRE7
NIT1
ZRT2

TADA2A

MOT3

N/A

N/A
N/A
ERMP1
CYBB
N/A
N/A

Protein of Unknown function
YHR131CP
N/A
FRT1

N/A

SYG1

XPR1

Name description

Localization

Number of
times
retrieved

snoRNA-binding rRNA-processing protein
mRNA-binding translational repressor

N
N/C

2
1

C/G

1

ES/ V

1

PM

1

ER/G/C
M

1
1

Cell division control protein 50
MiniChromosome maintenance protein 5
Anaphase Promoting Complex subunit 9
BNI1-related protein 1
Adenylate Cyclase & magnesium ion binding
component of 10 nm filaments of mother-bud
neck
Septin-related protein expressed during
sporulation
SWIRM domain-containing protein

ES
N
CD
CD
CD

1
1
1
1
1

CD

1

W/ S

1

C

1

Inner membrane assembly complex subunit 22
Nucleotide excision repair
Aminopeptidase Y
Ferric reductase PM
Nitrilase
low-affinity Zn(2+) transporter
Involved in cellular adjustment to osmotic
stress

M
N
V
PM
PM

2
1
1
1
1
1

N/C

1

Protein of Unknown function
Tail-anchored ER membrane protein of
unknown function
Signal Transduction

C

1

ER

1

PM/ER/G

1

Core component of transport protein particle
(TRAPP) complexes I-III
Vacuolar Protein Sorting
Component of the SPS plasma membrane
amino acid sensor system
COPII vesicle coat component
Mitochondrial inner membrane translocase
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3.4.2 Pbp1 deficiency alters the cell cycle
Due to the abundance of cell cycle proteins retrieved from the copurification interactome
we investigated the role of Pbp1 in cell cycle regulation. The ratio of cells in G1 phase compared
to G2 phase is of interest because these phases involve the synthesis of protein and therefore
likely involve RNA-binding proteins more than S phase. Pbp1-deficient cells displayed
significantly lower ratios of G1 to G2 cells compared wildtype cells when analyzed utilizing
Dunnett’s Method for t-test in JMP Pro14 (version 14.0) software (SAS Institute, Cary, NC,
USA), with a mean G1/G2 ratio of 8.17 compared to the wild type ratio of 11.98 because of an
increase in G2 and a decrease in G1. All statistical comparisons were made using Dunnett’s
Method for t-testing to maintain the wildtype strain as the primary comparison for all other
samples with a p-value cutoff of 0.05. Conversely, yeast deficient in PAS kinase (psk1psk2)
demonstrated higher G1/G2 ratios than wildtype because of a decrease in G2, with a mean
G1/G2 ratio of 18.15.

Figure 3-8: Representative histograms of the cell cycle as seen in wildtype, pbp1, and psk1psk2 cells.
Cells were fixed, stained with SYTOX-Green, and run through a Cytoflex Flow Cytometer. Stages of the cell cycle were
distinguished by Flow Jo software’s integrated cell cycle function. n≥2
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3.4.3 Pbp1 deficiency causes synthetic lethality with cell cycle binding partners
Cell cycle alterations were observed in Pbp1-deficient yeast, but the ways by which these
proteins affect the cell cycle are unknown. Four cell cycle proteins were chosen from the results
listed in Table 5 based on the ability to create single knockout strains. Growth assays were
performed to assess the viability of single knockout samples and double knockout samples; serial
dilutions were utilized to visualize suspected growth deficiencies and overall growth of strains.
The pbp1, spr28, and apc9 strains

WT

show growth comparable to that of the

pbp1

wildtype, but the spr28pbp1 and apc9pbp1

spr28

strains demonstrate severely stunted growth.

spr28pbp1

Spr28 is a septin-encoding protein, which

apc9

are conserved family that are required for

apc9pbp1

cytokinesis and the localization of other

fun19

proteins during cytokinesis and other cell

fun19pbp1

cycle stages (126, 127). Spr28 is highly
expressed during meiotic division when it

bnr1

localizes to the prospore membrane (128).

bnr1pbp1

Null mutants notably exhibit abnormal

Figure 3-9: Serial dilutions reveal growth defects.
No growth defects were observed in single-knockout
strains, but double-knockout strains show large defects.
All strains were constructed from the same background,
despite their various modifications.

vacuolar morphology and are
haploinsufficient, however, these mutants

remain viable (127-129). Apc9 is a subunit of the anaphase-promoting complex that functions as
a ubiquitin transferase. The complex aids the cell in transition from metaphase to anaphase in the
cell cycle by degrading anaphase inhibitory proteins and mitotic cyclins, which causes sister
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chromatids to separate, and the cell leaves the mitosis stage (130). Apc9 null mutant cells have
been observed to accumulate cells in the G2/M phase of the cell cycle because the metaphaseanaphase transition is delayed. Mutants have also been observed to have a decreased lifespan
(131). Our results are consistent with Pbp1 regulating cell cycle in that lacking Pbp1, Spr28, or
Apc9 is not detrimental to cell growth, but lacking Spr28 or Apc9 in conjunction with Pbp1
causes severe growth defects.
Fun19 also displays a synthetic lethal phenotype with Pbp1. The fun19 strain shows
slightly stunted growth from the wildtype, but the fun19pbp1 strain shows similar growth to
other double knockouts. Fun19 is a paralog of YOR338W that arose through the whole genome
duplication (132). Fun19 is a non-essential gene that is involved in chromatin binding and
remodeling through regulating histone acetylation (133, 134), and is required for sporulation
(135). The severe growth deficiencies shown in all four double knockout strains indicate that
Pbp1 and each cell cycle protein have overlapping functions that are stunted when both proteins
are lacking. Conversely the normal growth of single knockouts may indicate recovery functions
between Pbp1 and its binding partners. In contrast, Bnr1 shows a slight synthetic lethality with
Pbp1. Bnr1 belongs to the formin family, which are conserved proteins that promote the
assembly of actin filaments; these critical filaments aid remodeling of the actin cytoskeleton
(136). Bnr1 null mutants exhibit many abnormal traits related to cell cycle functions, like
abnormal actin cytoskeleton, abnormal budding pattern, and decreased chromosome maintenance
(137).
Further cell cycle analysis analogous to the above cell cycle data was attempted with
these cell cycle protein strains, however, differences were not found to be statistically significant.
Overall, trends show pbp1 strains have lower G1/G2 ratios than wildtype, and samples with Pbp1
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overexpression have ratios of G1/G2 higher than wildtype. psk1psk2 strains exhibit higher
G1/G2 ratios than wildtype, but PAS kinase overexpression has a similar effect as Pbp1
deficiency. Overexpressed PAS kinase samples have G1/G2 ratios resembling those of samples
lacking Pbp1. These trends are likely not statistically significant because of the high variability
seen in overexpression and double knockout strains.
3.4.4 Pbp1 sequesters Apc9 to stress granules
Previous studies have revealed colocalization of Pbp1 and Psk1 to stress granules (117),
and Pbp1 is known to sequester TORC1 to stress granules (116). Thus, Pbp1 may affect cell
cycle progression by sequestering cell cycle proteins to stress granules. To test this hypothesis,
Apc9-GFP was visualized along with Pbp1-RFP. Stress granule formation was induced by
glucose deprivation. Ptc6 colocalized to stress granules with Pbp1 (Figure 3-3), suggesting Pbp1
inhibits Apc9 activity through this sequestration.
3.4.5 Pbp1 sequesters mitochondrial phosphatase Ptc6 to stress granules
In addition to cell cycle effects, the role of Pbp1 in regulating Ptc6 was investigated due
to the metabolic alterations seen in ALS patients, as well as the shared functions of Ptc6 with
TORC1in mitophagy (138). Ptc6, a mitochondrial type 2C protein phosphatase, is required for
mitophagy in stationary phase cells (139). To determine if Pbp1 also regulates activity of its
binding partner Ptc6 via sequestration to stress granules, confocal microscopy was performed.
Ptc6-GFP was used to visualize the location of Ptc6 and Pbp1-RFP was used to visualize the
location of Pbp1. Stress granule formation was induced by glucose deprivation. Pbp1 and Ptc6
were shown to colocalize within the cell to cytoplasmic foci (Figure 3-4). This suggests that
Pbp1 sequesters Ptc6 to stress granules when the cell is under cellular stress, thus regulating its
activity.
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3.4.6 Pbp1 deficient yeast exhibit increased mitophagy and mitophagy is restored to
normal in Pbp1/Ptc6 deficient yeast
Mitophagy is the process of clearing damaged mitochondria from the cell. It is thought
that improper mitophagy can lead to the accumulation of dysfunctional or damaged
mitochondria, which contribute to neurodegeneration in ALS patients (140). Because Ptc6 has
known involvement in mitophagy, Ptc6 was chosen for further investigation. Mitophagy assays
were used to test our hypothesis that Pbp1 is inactivating Ptc6 by sequestration assays. If Pbp1 is
absent from the cell, Ptc6 may not be sequestered to stress granules, allowing for mitophagy to
occur.
Mitophagy was induced
through 48 hour-growth in
YPL and mitophagy was
quantified by the amount of
degraded OM45-GFP,
measured through western blot.
ATG1 was included as a
control, as it should block
mitophagy pathways. The
level of mitophagy seen in
Ptc6 matched what has been

Figure 3-10: Colocalization of Pbp1 and Ptc6.
Ptc6-GFP fusion yeast (ThermoFisher) was transformed with Pbp1-RFP (JG1669),
grown under glucose deprivation, and imaged using an Olympus Fluoview. confocal
microscope.

reported in previous studies, with mitophagy being lowered in this strain. Pbp1 yeast showed
significantly elevated levels of mitophagy, suggesting a novel role of Pbp1 in regulating
mitophagy within the cell. In addition, Pbp1Ptc6 yeast showed mitophagy levels similar to wild-
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type. This was unexpected as Ptc6 has been reported as an essential gene necessary for
mitophagy. The remaining strains tested
revealed no significant changes. One-way
ANOVA was performed using JMP Pro14
(version 14.0) software (SAS Institute, Cary,
NC, USA) with Tukey’s post-hoc test.
3.4.7 PTC6 deficient yeast exhibit
mitochondrial alterations
Due to the significant increase in

Figure 3-11: Pbp1 yeast display increased levels of mitophagy.
Mitophagy assays were conducted using the OM45-GFP
processing assay developed by Kanki et al. Mitophagy was
induced through growth in YPL and the amount of degraded GFP
was measured as a marker for mitophagy. Bands were quantified
using ImageJ. Significance was determined by one-way ANOVA
and Tukey’s post-hoc test. n=2.

mitophagy in Pbp1 deficient yeast and the significant decrease in mitophagy in Ptc6 deficient
yeast, mitochondria health was measured in each of the strains tested for the mitophagy assay.
First, mitochondria content was quantified using flow cytometry. Mitochondria were tagged
with OM45-GFP and endoplasmic reticulum was tagged with RFP. Endoplasmic reticulum was
used as a cellular control. Our results show that PTC6 deficient yeast contain significantly more
mitochondria. However, PTC6/Pbp1 deficient yeast show levels similar to WT. One-way
ANOVA was performed using JMP Pro14 (version 14.0) software (SAS Institute, Cary, NC,
USA) with Tukey’s post-hoc test.
This change in mitochondria content suggested that a change in respiration may also be
seen due to the elevated mitochondrial content. Plate respiration assays were utilized to first
determine if any noticeable respiratory differences could be detected. Each strain was grown up
overnight and 1:10-fold serial dilutions were performed and plated 1:100-fold serial dilutions
were performed from the overnight and plated onto both glucose (a fermentative carbon source)
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A.

B.

Figure 3-12: Evidence for Ptc6 regulation of respiration.
(A) Mitochondria was quantified using flow cytometry. OM45-GFP was used as a marker for
mitochondrial content and the ER was quantified using Sec63-RFP, a protein in the ER. The ER was
included as a control of overall cellular content. (B) Spot dilutions revealed increased respiration in Ptc6
yeast. Together, these results suggest the elevated mitochondrial content is contributing to elevated
respiration.

and glycerol/ethanol (a respiratory carbon source). Following two days of growth, it was
revealed that Ptc6 deficient yeast showed increased colony mass.
3.5 Discussion
There are approximately 16,000 Americans living with ALS at any given moment. With
a typical survival time of only 2-5 years, ALS is a grim diagnosis with few treatment options.
Fortunately, advances in technology have allowed for a more in-depth understanding of the
pathways involved in the disease and potential drug targets (141). Recently, ataxin-2 has been
identified as a promising therapeutic target for ALS. It has been shown that intermediate-length
polyglutamine expansions in the ataxin-2 gene increases the risk of ALS. Furthermore, it has
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been shown that by lowering the levels of ataxin-2, it is possible to mitigate disease caused by
TDP-43 proteinopathy in yeast, flies, and mice (142). This study focuses on identifying proteins
that interact with Pbp1, the yeast homolog of ataxin-2, to elucidate the molecular pathways that
may be affected during neurodegeneration.
A large-scale yeast interactome study identified 32 novel putative binding partners
through yeast-two hybrid (seven binding partners) and mass spectrometry (24 binding partners).
This has largely expanded the role of Pbp1 in yeast, which includes six proteins that are involved
in RNA processing, a known role for Pbp1, five proteins involved in protein transportation, eight
cell cycle proteins, and 13 proteins with other unknown functions. In addition, 21 of the 32
identified binding partners have a human homolog, suggested a possible conserved function
between yeast and man.
Eight cell cycle-related binding partners were found for Pbp1, comprising one-fourth of
the newly identified 32 binding partners. Due to this large number of cell cycle proteins
identified in the interactome study, the effects of Pbp1 on cell cycle was analyzed. Flow
cytometry was utilized to visualize the cell cycle in strains of interest. Single knockout strains of
Pbp1 and PAS kinase were assessed alongside wildtype (see Figure 3-3). This revealed that Pbp1
deficiency cause more cells to remain in G2 phase, giving a lower ratio of G1/G2. PAS kinase
deficiency caused fewer cells to remain in G2 phase, giving a higher ratio of G1/G2. These
opposing effects are likely explained by the individual protein’s unique binding partners’
functionalities being altered.
PAS kinase is known to regulate carbohydrate storage and translation through activation
of its substrates, so PAS kinase deficient cells lack a key activator of proteins that contribute to
the growth of the cell (143, 144); therefore, PAS kinase deficient cells likely require more time
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to pass through the restriction point of G1 phase, causing a higher G1/G2 ratio. Pbp1 is known to
be involved in mRNA stability and R-loop regulation in addition to regulation through
sequestration to stress granules (58). Pbp1 deficient cells may progress through G1 phase quicker
because Pbp1 is not in the cell to sequester growth and proliferation proteins to stress granules. A
quicker progression through G1 phase would lower the G1/G2 ratio of Pbp1 deficient cells. This
prompted an investigation into the binding partners of Pbp1 that are associated with the cell
cycle.
Of the eight cell cycle-associated Pbp1 binding partners identified, four were not lethal
null mutants, and these were assessed through growth assays in conjunction with Pbp1
deficiency. Overall, none of the single knockout strains assessed (pbp1 apc9, spr28, fun19, bnr1)
had significant growth deficiencies, however, when strains were Pbp1-deficient in addition,
severe growth deficiencies were apparent (see Figure 3-4). This indicates that Pbp1 is a crucial
activator of proteins that can recover lost functions of these investigated cell cycle proteins.
Apc9 was investigated further and shown to colocalize with Pbp1 at stress granules, where its
activity may be inhibited (see Figure 3-3).
Through the yeast two-hybrid assay we also identified Ptc6 as a novel interacting partner
of Pbp1. Ptc6 (also referred to as Aup1 or PPP2 in yeast) is a serine/threonine phosphatase that
is localized to the mitochondria. Ptc6 is necessary for efficient mitophagy and cell survival (139).
This was validated through the OM45-GFP processing assay, as PTC6 yeast demonstrated
decreased levels of mitophagy. Interestingly, PBP1 yeast exhibited significantly increased levels
of mitophagy. This result combined with our colocalization assays creates a model for how Pbp1
is interacting with Ptc6. We hypothesize that when Pbp1 interacts with Ptc6 it sequesters it to
the stress granule, effectively deactivating Ptc6 function in the cell and decreasing mitophagy
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pathways (see Figure 3-7). When Pbp1 is absent from the cell, Ptc6 is not sequestered to the
stress granules, resulting in an increase in Ptc6 function and increased mitophagy. This result is
especially interesting when looking at the context of ALS. In ALS, mitophagy pathways are
often blocked, allowing for the accumulation of damaged mitochondria in the cell and
contributing to neurodegeneration (140). Elevated mitophagy in Pbp1 yeast suggests yet another
benefit of targeting Pbp1/ataxin-2 for ALS therapy, as lowering levels of Pbp1/ataxin-2 will
result in increased mitophagy and decreased accumulation of damaged mitochondria.
This difference in mitophagy prompted a deeper understanding of the mitochondria in
these yeast strains. Flow cytometry assays revealed elevated mitochondria in PTC6 yeast. This
is supported by the mitophagy assays, as an inability to perform mitophagy would result in
elevated levels of mitochondria in the cell. Furthermore, PTC6 yeast appear to have increased
respiration as shown by plate assay. As such, further characterization of the mitochondria is
needed to determine if the yeast is accumulating damaged and dysfunctional mitochondria in the
cell. This includes viewing mitochondrial morphology via confocal microscopy and measuring
mitochondrial respiration via the Seahorse XF Cell Mito Stress Test.
In addition to the mitochondrial phenotypes seen in Ptc6 yeast, Ptc6 yeast has been
shown to be sensitive to rapamycin. This is very interesting because TORC1 is also sensitive to
rapamycin. It is known that Pbp1 sequesters TORC1 to stress granules, but it is unknown how
that happens. It is possible that Pbp1 is working through Ptc6 to sequester TORC1 to stress
granules. This would also suggest that the Ptc6 sensitivity to rapamycin could in part be due to it
sequestering TORC1 to stress granules. To test this theory, TORC1-GFP could be transformed
into Ptc6 yeast with Pabp1-RFP allowing for sequestration of TORC1 to stress granules to be
monitored. If Ptc6 is responsible for sequestration, then TORC1 will not colocalize with Pab1-
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Figure 3-13: Possible models of Pbp1/ataxin-2 sequestration of Ptc6 to stress granules.
(1) Pbp1 activation by PAS kinase results in sequestration of both Pbp1 and Ptc6, thus decreasing the function of Pbp1.
(2) When Pbp1 is absent from the cell, Ptc6 is no longer sequestered to stress granules, remaining functional and
possibly contributing to the increased mitophagy seen in Pbp1 yeast. Possible models of Ptc6 dependent sequestration
of TORC1 to stress granules. (3) Ptc6 is required for TORC1 sequestration to stress granules. In its absence, TORC1 is not
sequestered to stress granules. (4) Ptc6 is not required for TORC1 sequestration to stress granules.

RFP in the stress granules. If TORC1 does colocalize to the stress granules, it would suggest that
Pbp1 is regulating the Ptc6 and TORC1 pathways separately.
Through the identification of these 32 novel interacting partners of Pbp1 and the
characterization of two identified ways Pbp1 affects cell health—through cell cycle proteins and
Ptc6—, we have further solidified the importance of understand the role of Pbp1/ataxin-2 in
ALS. By understanding both its upstream and downstream pathways, we can understand how to
best utilize it as a therapeutic target to help individuals with the disease.
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CHAPTER 4: Concluding Remarks and Future Directions
4.1 Ataxin-2 is an important cellular regulator involved in disease
Ataxin-2 is a diverse protein with multi-faceted functions that is conserved through
eukaryotic organisms, form S. cerevisiae to M. musculus and H. sapiens. The diverse functions
of ataxin-2 can be divided into two categories; RNA control and physiological functions. Ataxin2 regulates R-loops and aids in mRNA stability and translation (7). It also helps form stress
granules by recruiting proteins to the phase-separated granule (30). Physiologically, ataxin-2 has
been shown to help maintain circadian rhythmicity and regulate proteins like TORC1 (8). When
these functions go awry, cells experience impaired stress responses, metabolic dysfunction, or
genome instability. Additionally, ataxin-2 has been linked to Amyotrophic Lateral Sclerosis.
Understanding the pathways in which ataxin-2 is involved will elucidate the ways in which
ataxin-2 contributes to neurodegeneration and how this can be exploited to treat disease.
Ataxin-2 is activated by PAS kinase (Figure 1-3), a serine/threonine kinase with
evolutionary conservation in eukaryotes. While the activation relationship between PAS kinase
and ataxin-2 is known, the effects of deregulation of PAS kinase on ataxin-2 and its functions are
not known (8). Although both PAS kinase and ataxin-2 have yeast homologs, making S.
cerevisiae, a good model, ALS is a neurodegenerative disease, which calls for an organism
model with neurons for more complete investigation.
4.2 PAS kinase deficiency reduces ataxin-2 abundance in mice
While the interaction between PAS kinase and ataxin-2 (Pbp1) was established in a yeast
model, ALS model mice were used to observe this interaction in a mammalian model. Mice that
lacked PAS kinase were utilized to detect the effects of PAS kinase deficiency in mammals. As
seen in Figure 2-4, no observable differences of general ataxin-2 abundance were observed in
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PAS kinase-deficient mice who consumed a normal diet, but high-fat, high sugar dieting PAS
kinase-deficient mice demonstrated significantly lower levels of ataxin-2. This indicates that
inhibition of PAS kinase can reduce the amount of ataxin-2 in cells, especially in cells under
stress caused by Western-style diets. This makes PAS kinase a potential alternative target to
ataxin-2 for therapeutics. The question, however, of what these manipulations may cause in the
cell arises.
4.3 PAS kinase and Pbp1 cause deviation from wildtype cell cycle
Flow cytometric analysis of the cell cycle (Figure 3-2) reveals that Pbp1 and PAS kinase
deficiencies confer opposite effects on the overall cell cycle. Because proteins are synthesized in
the G1 and G2 phases of the cell cycle, we compared ratios of G1 phase cells to G2 phase cells
across the strains. Pbp1 deficiency decreases the ratio of G1 to G2 cells compared to wildtype,
while PAS kinase deficiency increases the ratio. Analysis of the effects of cell-cycle related
binding partners show variability too high to conclude definitive changes. Although PAS kinase
deficiency has been shown to reduce Pbp1 abundance, and, therefore, confer similar phenotypic
outcomes as Pbp1-deficiecncy, the proteins each have unique binding partners that are affected
by their loss. PAS kinase is known to regulate carbohydrate storage and translation through
activation of its substrates, so PAS kinase deficient cells lack a key activator of proteins that
contribute to the growth of the cell (143, 144); therefore, PAS kinase deficient cells likely
require more time to pass through the restriction point of G1 phase, causing a higher G1/G2
ratio.
Pbp1 is known to be involved in mRNA stability and R-loop regulation in addition to
regulation through sequestration to stress granules (58). Pbp1 deficient cells may progress
through G1 phase quicker because Pbp1 is not in the cell to sequester growth and proliferation
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proteins to stress granules. A quicker progression through G1 phase would lower the G1/G2 ratio
of Pbp1 deficient cells. To investigate the cause of these changes in Pbp1 deficient cells, we
identified and analyzed cell cycle-related binding partners of Pbp1.
4.4 Pbp1 affects the cell cycle through its binding partners
To investigate the downstream effects of ataxin-2 reduction, binding partners of Pbp1
were identified through a yeast two-hybrid and mass spectrometry. Since the health of cells with
deregulation of PAS kinase and ataxin-2 was of interest, Pbp1 binding partners with functions
related to the cell cycle were analyzed—Spr28, Fun19, Apc9, and Bnr1. After construction of
double knockout strains, growth assays were performed to assess the overall growth abilities of
the strains, as seen in Figure 3-3. Double knockout strains show synthetic lethality while single
knockout strains grow comparably to wildtype, indicating that Pbp1 shares vital roles with cell
cycle proteins of various functions.
4.5 Future directions
The relationship between PAS kinase downregulation and the consequential effect of
ataxin-2 reduction has been observed in yeast and mice, but this should also be considered in a
human cell model. Due to the low levels of expression of these proteins, detection of successful
knockdown was inconclusive, and previous attempts using embryonic kidney cells were,
therefore, unsuccessful. Using a neuronal cell type would likely improve success.
Conclusive flow cytometric analysis of the cell cycle protein knockouts was unsuccessful
because the samples showed high variability in the percentages of cells in each stage of the cell
cycle. This is could be caused by high RNA content in the cells that could not be removed with
RNase digestion, or the samples could truly have very different outcomes to loss of cell cycle
proteins. To test if the variability stems from high RNA content interfering with analysis,
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samples that showed high variability should be revisited using a DNA-specific stain, like DAPI.
Additionally, Northern Blot analysis could be used to quantify relative RNA amounts compared
to wildtype.
These downstream effects of manipulation of the PAS kinase-ataxin-2 activation pathway
causes observable changes in the functions of the cell, however, these changes are not, by
themselves, observably detrimental to the cell. When manipulating PAS kinase or ataxin-2,
however, mutations in binding partners should be avoided to maintain functional cells.
Understanding the pathways in which ataxin-2 is involved is crucial to understanding the
ways in which ataxin-2 is involved in neurodegeneration and degenerative disease.
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